Reactive hydrogel-forming formulations and related methods
By using a hydrogel-forming composition of bifunctional polyalkylene oxide, the hydrogel tissue sealant for cross-linking reactions solves the problem of tissue sealing in pneumothorax and other surgical applications, significantly reducing the incidence of pneumothorax and Complication risk improves the safety of the surgery.
Patent Information
- Application Number
- CN202411054992.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2020-03-20
- Filing Date
- 2021-03-19
- Publication Date
- 2024-11-22
AI Technical Summary
Pneumothorax is a common complication in lung biopsy operations. The prior art is difficult to effectively solve the problem of tissue sealing in pneumothorax and other surgical applications, especially during lung biopsy, which increases the patient's hospital stay and complication risk.
A hydrogel-forming composition based on bifunctional polyalkylene oxide is developed, containing crosslinking agents and proteins, to form a hydrogel tissue sealant through crosslinking reactions for adhesion to the pleura to seal tissue and reduce pneumothorax. Risks that occur.
This technology can quickly form hydrogel tissue sealants, significantly reducing the incidence and complication risk of pneumothorax, and improving the safety of surgery and the patient's hospital stay.
Smart Images

Figure CN118987323A_ABST
Abstract
Description
[0001] This application is a divisional application of the Chinese patent application with application number 202180032648.5 and invention name “Reactive hydrogel-forming preparations and related methods”. The parent application is the PCT international patent application PCT / US2021 / 023359 filed on March 19, 2021, which entered the Chinese national phase. Technical Field
[0002] Compositions and methods related to hydrogel tissue sealants are generally described. Background Art
[0003] Pneumothorax is a complication that becomes a problem in lung biopsy operation, wherein air enters the pleural space due to the puncture of the parietal pleura and the visceral pleura. Pneumothorax has caused great concern among clinicians who perform percutaneous lung biopsy and patients who suffer from percutaneous lung biopsy. The incidence of pneumothorax in patients who suffer from percutaneous lung biopsy has been reported to be about 9% to about 54% of patients anywhere, averaging about 15%. In addition, about 7% of all percutaneous lung biopsies on average cause pneumothorax that requires chest tube to be placed in the patient, which subsequently causes an average hospital stay of about 3 days. Factors that improve the risk of pneumothorax include increased patient age, obstructive lung disease, increased depth of lesions, increased time for needles to pass through the pleura for many times, and increased fissures. Pneumothorax can occur immediately during or after the lung biopsy operation. In addition, other complications of percutaneous lung biopsy include hemoptysis, hemothorax, infection, and air embolism. It would be beneficial to develop new hydrogel tissue sealants and related methods that have the ability to adhere to tissue (eg, pleura) and / or seal tissue (eg, pleura) to address pneumothorax and other surgical applications. Summary of the invention
[0004] Compositions and methods for forming hydrogel tissue sealants are generally described.In some cases, the present subject matter relates to related products, alternative solutions to a particular problem, and / or a variety of different uses of one or more systems and / or articles.
[0005] In some embodiments, a hydrogel forming composition for forming a hydrogel tissue sealant is described. In certain embodiments, the hydrogel forming composition comprises a first component comprising a crosslinker, wherein the crosslinker is a difunctional polyalkylene oxide-based component of the formula:
[0006] G-LM-PEG-LM-G;
[0007] in:
[0008] PEG is polyethylene glycol;
[0009] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0010] Each G is a leaving group independently selected from the following: N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl and trifluoroethanesulfonyl (tresyl). In certain embodiments, the hydrogel forming composition comprises a second component containing a protein capable of being cross-linked with a cross-linking agent. In some embodiments, the hydrogel forming composition comprises one or more solvents capable of dissolving the first component and the second component, and a surfactant. In certain embodiments, when the first component, the second component and the surfactant are all dissolved in the one or more solvents, the cross-linking agent cross-links with the protein to form a hydrogel tissue sealant.
[0011] In some embodiments, the hydrogel-forming composition for forming a hydrogel tissue sealant comprises a cross-linking agent, wherein the cross-linking agent is a difunctional polyalkylene oxide-based component of the formula:
[0012] G-LM-PEG-LM-G;
[0013] in:
[0014] PEG is polyethylene glycol;
[0015] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0016] Each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazole, and trifluoroethanesulfonyl. In certain embodiments, the hydrogel-forming composition comprises a protein capable of being cross-linked with a cross-linking agent, one or more solvents capable of dissolving the first component and the second component, and a surfactant, wherein when the cross-linking agent, the protein, and the surfactant are all dissolved in the one or more solvents, the cross-linking agent cross-links with the protein to form a hydrogel tissue sealant.
[0017] According to certain embodiments, the hydrogel-forming composition for forming a hydrogel tissue sealant comprises a first component comprising a cross-linking agent, wherein the cross-linking agent is a difunctional polyalkylene oxide-based component of the formula:
[0018] G-LM-PEG-LM-G;
[0019] in:
[0020] PEG is polyethylene glycol;
[0021] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0022] Each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazole, and trifluoroethanesulfonyl. In some embodiments, the hydrogel-forming composition comprises a second component comprising a protein capable of being cross-linked with a cross-linking agent, and one or more solvents capable of dissolving the first component and the second component, wherein when the first component and the second component are dissolved in the one or more solvents, after the first component dissolved in the one or more solvents is mixed with the second component, the cross-linking agent cross-links with the protein and the gel time is less than or equal to 20 seconds to form a hydrogel tissue sealant.
[0023] According to some embodiments, the hydrogel-forming composition for forming a hydrogel tissue sealant comprises a first component comprising a cross-linking agent, wherein the cross-linking agent is a difunctional polyalkylene oxide-based component of the formula:
[0024] G-LM-PEG-LM-G;
[0025] in:
[0026] PEG is polyethylene glycol;
[0027] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c-C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0028] Each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimido, N-oxyphthalimido, nitrophenoxy, N-oxyimidazole, and trifluoroethanesulfonyl. In certain embodiments, the hydrogel-forming composition comprises a second component containing a protein capable of being cross-linked with a cross-linking agent, a first solvent capable of dissolving the first component, and a second solvent capable of dissolving the second component, wherein when the second component is dissolved in the second solvent, the pH of the solution of the second component in the second solvent is greater than or equal to 10.2 and less than or equal to 10.6; and wherein when the first component is dissolved in the first solvent and combined with the solution of the second component in the second solvent, a cross-linked solution of the first component and the second component is formed.
[0029] In certain embodiments, the hydrogel-forming composition for forming a hydrogel tissue sealant comprises a first component comprising a cross-linking agent, wherein the cross-linking agent is a difunctional polyalkylene oxide-based component of the formula:
[0030] G-LM-PEG-LM-G;
[0031] in:
[0032] PEG is polyethylene glycol;
[0033] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0034] Each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl. According to certain embodiments, the hydrogel-forming composition comprises a second component containing a protein capable of being cross-linked with a cross-linking agent; and one or more solvents capable of dissolving the first component and the second component, such that when the first component and the second component are mixed separately with the one or more solvents, at least the second component is capable of having a dissolution time of less than or equal to 30 seconds at 25°C.
[0035] In certain embodiments, a method of forming a hydrogel tissue sealant is described. In some embodiments, the method comprises dissolving a first component in a first solvent, wherein the first component comprises a cross-linking agent, wherein the cross-linking agent is a difunctional polyalkylene oxide-based component of the formula:
[0036] G-LM-PEG-LM-G;
[0037] in:
[0038] PEG is polyethylene glycol;
[0039] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 )d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0040] Each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazole, and trifluoroethanesulfonyl. In certain embodiments, the method comprises dissolving a second component in a second solvent, wherein the second component comprises a protein capable of being cross-linked with a cross-linking agent, and combining the dissolved first component with the dissolved second component to form a hydrogel-forming composition comprising a cross-linking agent, a protein, and a surfactant to initiate cross-linking of the cross-linking agent with the protein to form a hydrogel tissue sealant.
[0041] According to certain embodiments, a method of forming a hydrogel tissue sealant comprises dissolving a first component in a first solvent, wherein the first component comprises a crosslinker, wherein the crosslinker is a difunctional polyalkylene oxide-based component of the formula:
[0042] G-LM-PEG-LM-G;
[0043] in:
[0044] PEG is polyethylene glycol;
[0045] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0046] Each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl. In some embodiments, the method comprises dissolving a second component in a second solvent, wherein the second component comprises a protein capable of being cross-linked with a cross-linking agent, and combining the dissolved first component with the dissolved second component to form a hydrogel-forming composition comprising the cross-linking agent and the protein, thereby initiating cross-linking of the cross-linking agent with the protein to form a hydrogel tissue sealant, such that the cross-linking is characterized by a gel time of less than or equal to 20 seconds.
[0047] In some embodiments, a method of forming a hydrogel tissue sealant comprises dissolving a first component in a first solvent to form a solution of the first component, wherein the first component comprises a cross-linking agent, wherein the cross-linking agent is a difunctional polyalkylene oxide-based component of the formula:
[0048] G-LM-PEG-LM-G;
[0049] in:
[0050] PEG is polyethylene glycol;
[0051] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c-C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d- C(O)-containing amide-containing diradical, wherein d is an integer from 1 to 10; the formula -(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0052] Each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl. In certain embodiments, the method comprises dissolving a second component in a second solvent to form a solution of the second component, wherein the second component comprises a protein capable of being cross-linked with a cross-linking agent, and wherein the pH of the solution of the second component is greater than or equal to 10.2 and less than or equal to 10.6, and combining the solution of the first component with the solution of the second component to form a hydrogel-forming composition comprising a cross-linking agent and a protein, thereby initiating cross-linking of the cross-linking agent with the protein to form a hydrogel tissue sealant.
[0053] According to certain embodiments, a method of forming a hydrogel tissue sealant comprises dissolving a first component in a first solvent, wherein the first component comprises a crosslinker, wherein the crosslinker is a difunctional polyalkylene oxide-based component of the formula:
[0054] G-LM-PEG-LM-G;
[0055] in:
[0056] PEG is polyethylene glycol;
[0057] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomer diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments. And
[0058] Each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimido, N-oxyphthalimido, nitrophenoxy, N-oxyimidazole, and trifluoroethanesulfonyl. In some embodiments, the method comprises dissolving a second component in a second solvent, wherein the second component comprises a protein capable of being cross-linked with a cross-linking agent, wherein the dissolution time of the second component in the second solvent at 25° C. is less than or equal to 30 seconds; and combining the dissolved first component with the dissolved second component to form a hydrogel-forming composition comprising a cross-linking agent and a protein, thereby initiating cross-linking of the cross-linking agent with the protein to form a hydrogel tissue sealant.
[0059] In some embodiments, a method of forming a hydrogel tissue sealant comprises forming a hydrogel-forming composition comprising a cross-linking agent that is a difunctional polyalkylene oxide-based component of the formula:
[0060] G-LM-PEG-LM-G;
[0061] in:
[0062] PEG is polyethylene glycol;
[0063] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 )d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0064] Each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl. In some embodiments, the solution comprises a protein capable of being cross-linked with a cross-linking agent, and a surfactant, wherein the hydrogel-forming composition, after formation, causes the cross-linking agent to initiate cross-linking with the protein, thereby forming a hydrogel tissue sealant.
[0065] In some embodiments, a method of sealing tissue is described. In certain embodiments, the method comprises delivering a hydrogel-forming composition to a tissue site, wherein the hydrogel-forming composition comprises a reaction product of:
[0066] The first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0067] G-LM-PEG-LM-G;
[0068] in:
[0069] PEG is polyethylene glycol;
[0070] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c-C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0071] each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; and
[0072] A second component comprises a protein capable of being cross-linked with a cross-linking agent. In certain embodiments, the hydrogel-forming composition further comprises a surfactant.
[0073] According to certain embodiments, a method of sealing tissue comprises delivering a hydrogel-forming composition to a tissue site, wherein the hydrogel-forming composition is the reaction product of:
[0074] A solution of a first component comprising a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0075] G-LM-PEG-LM-G;
[0076] in:
[0077] PEG is polyethylene glycol;
[0078] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c-C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0079] each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; and
[0080] A solution of a second component comprising a protein capable of being cross-linked with a cross-linking agent, wherein the pH of the solution of the second component is greater than or equal to 10.2 and less than or equal to 10.6.
[0081] According to some embodiments, a method of sealing tissue comprises delivering a hydrogel-forming composition to a tissue site, wherein the hydrogel composition comprises a reaction product of:
[0082] The first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0083] G-LM-PEG-LM-G;
[0084] in:
[0085] PEG is polyethylene glycol;
[0086] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0087] each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; and
[0088] The second component comprises a protein capable of being cross-linked with a cross-linking agent. In certain embodiments, the method comprises forming a hydrogel tissue sealant at a tissue site by a cross-linking reaction characterized by a gel time of less than or equal to 20 seconds.
[0089] In certain embodiments, a kit for forming a hydrogel tissue sealant is described, wherein the kit contains a first component contained within a first container, wherein the first component comprises a cross-linking agent, wherein the cross-linking agent is a difunctional polyalkylene oxide-based component of the formula:
[0090] G-LM-PEG-LM-G;
[0091] in:
[0092] PEG is polyethylene glycol;
[0093] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d- represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0094] Each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl. In certain embodiments, the kit comprises: a second component contained in a second container, wherein the second component comprises a protein capable of being cross-linked with a cross-linking agent, and a surfactant.
[0095] According to some embodiments, a kit for forming a hydrogel tissue sealant comprises: a first component in powder form contained within a first container, wherein the first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0096] G-LM-PEG-LM-G;
[0097] in:
[0098] PEG is polyethylene glycol;
[0099] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d-OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0100] Each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimido, N-oxyphthalimido, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl. In some embodiments, the kit comprises: a second component in powder form contained in a second container, wherein the second component comprises a protein capable of being cross-linked with the cross-linking agent; a first aqueous hydration solution contained in a third container, wherein the first aqueous hydration solution is capable of dissolving the first component; and a second aqueous hydration solution contained in a fourth container, wherein the second aqueous hydration solution is capable of dissolving the second component.
[0101] In certain embodiments, a kit for forming a hydrogel tissue sealant comprises: one or more syringes collectively comprising at least three separate containers, wherein a first container comprises a first component in powder form, a second container comprises a second component in powder form, and at least a third container comprises one or more solvents, wherein the one or more syringes are configured such that the first container and the second container can be placed in fluid communication with at least the third container comprising the one or more solvents to facilitate mixing of the first component with the one or more solvents to form a solution of the first component and to facilitate mixing of the second component with the one or more solvents to form a solution of the second component, and wherein the one or more syringes are further configured to mix the solution of the first component with the solution of the second component to form a cross-linked solution of the first component and the second component that is capable of forming a hydrogel tissue sealant; wherein the first component comprises an electrophilic biodegradable polymer, and the second component comprises a nucleophilic biodegradable polymer capable of cross-linking with the electrophilic biodegradable polymer.
[0102] According to some embodiments, the hydrogel-forming composition for forming a hydrogel tissue sealant comprises a first component comprising a cross-linking agent, the cross-linking agent being a difunctional polyalkylene oxide-based component of the formula:
[0103] G-LM-PEG-LM-G;
[0104] in:
[0105] PEG is polyethylene glycol;
[0106] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0107] Each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl. In certain embodiments, the hydrogel-forming composition comprises a second component comprising a protein capable of being cross-linked with a cross-linking agent, and one or more solvents, wherein the first component and the second component are dissolved in the one or more solvents.
[0108] In certain embodiments of the hydrogel-forming composition, the difunctional polyalkylene oxide-based component has the formula G-LM-(OCH 2 CH 2 ) n O-LM-G, wherein n is an integer from 10 to 500, preferably an integer from 50 to 200.
[0109] In certain embodiments of the hydrogel-forming composition, the leaving group G in the difunctionalized polyalkylene oxide-based component is an N-oxysuccinimide group.
[0110] In certain embodiments of the hydrogel-forming composition, the bifunctional linking moiety LM in the bifunctional polyalkylene oxide-based component is selected from -(CH 2 ) b -C(O)- and -C(O)-(CH 2 ) c -C(O)-, wherein both b and c are integers of 1 to 10.
[0111] In certain embodiments of the hydrogel-forming composition, the difunctionalized polyalkylene oxide-based component is selected from:
[0112]
[0113] In both formulae, n is an integer of 10 to 500, preferably an integer of 50 to 200.
[0114] In certain embodiments of the hydrogel-forming composition, the protein is selected from the group consisting of human serum albumin, recombinant human serum albumin, and animal-derived albumin.
[0115] In certain embodiments of the hydrogel-forming compositions, the protein is recombinant human serum albumin.
[0116] In certain embodiments of the hydrogel-forming composition, the composition further comprises a surfactant dissolved in the one or more solvents.
[0117] In certain embodiments of the hydrogel-forming composition, the surfactant is selected from non-functionalized PEG, dextran sulfate, poloxamer, polysorbate, oil, silicone, stearate and / or glycol, wherein the non-functionalized PEG preferably has a weight average molecular weight of 1000 g / mol to 40000 g / mol.
[0118] In certain embodiments of the hydrogel-forming composition, the one or more solvents comprise water in an amount of 50 wt.% to 100 wt.%, preferably 90 wt.% to 100 wt.%, based on the total amount of solvents.
[0119] In certain embodiments of the hydrogel-forming composition, the difunctionalized polyalkylene oxide-based component is selected from:
[0120]
[0121] wherein in both formulae, n is an integer from 10 to 500, preferably an integer from 50 to 200;
[0122] The protein was recombinant human serum albumin;
[0123] The surfactant is non-functionalized PEG; and
[0124] Water accounts for 90 wt. % or more of the total amount of the one or more solvents.
[0125] In certain embodiments of the hydrogel-forming composition, the composition further comprises a cross-linking initiator, an antioxidant, and / or a radiopaque agent.
[0126] In certain embodiments of the hydrogel-forming composition, the composition comprises a base or alkaline buffer, preferably a carbonate and / or bicarbonate salt.
[0127] In certain embodiments of the hydrogel-forming composition, the composition comprises an antioxidant, preferably butylated hydroxyanisole, butylated hydroxytoluene, propyl gallate d-alpha tocopheryl polyethylene glycol-1000 succinate or sodium metabisulfite, and / or mixtures thereof.
[0128] In certain embodiments of the hydrogel-forming composition, the composition comprises a radiopaque agent, preferably gold, silver, iodine, potassium chloride, barium sulfate, iohexol, or diatrizoate, and / or mixtures thereof.
[0129] In certain embodiments of the hydrogel-forming composition, a first component of the composition is dissolved in a first solvent.
[0130] In certain embodiments of the hydrogel-forming composition, the second component of the composition is dissolved in the second solvent.
[0131] In certain embodiments of the hydrogel-forming composition, the pH of the second component dissolved in the second solvent is from 10.2 to 10.6.
[0132] In certain embodiments, a kit for forming a hydrogel tissue sealant comprises:
[0133] A first container comprising a first component, the first component comprising a cross-linking agent as defined in the present disclosure; a second container comprising a second component, the second component comprising a protein, preferably a protein selected from human serum albumin, recombinant human serum albumin and albumin of animal origin; and optionally, one or more additional containers comprising one or more solvents for dissolving the first component and the second component, preferably water.
[0134] In certain embodiments, the kit comprises: a first container comprising a first component; a second container comprising a second component; and a third container comprising a solvent, preferably water, for dissolving the first component and the second component.
[0135] In certain embodiments, the kit comprises: two syringes, wherein the first syringe comprises a first container and a second container; and wherein the second syringe comprises a third container; wherein the first component and the second component contained in the syringes are in powder form; wherein the first syringe and the second syringe are configured to be fluidly connectable to each other so that the first container and the second container can be placed in fluid communication with the third container to facilitate mixing of the first component and the second component with a solvent to form a solution of the first component in the first container and a solution of the second component in the second container, and wherein the first syringe is further configured to mix the solution of the first component with the solution of the second component to form a hydrogel-forming composition for forming a hydrogel tissue sealant. In certain embodiments, such a kit comprises: a first container comprising a first component; a second container comprising a second component; a third container comprising a solvent for dissolving the first component, preferably water; and a fourth container comprising a solvent for dissolving the second component, preferably water; and may also comprise: two syringes, wherein the first syringe comprises the first container and the second container; and wherein the second syringe comprises the third container and the fourth container; wherein the first component and the second component are in powder form; wherein the first syringe and the second syringe are configured to be fluidly connectable to each other so that the first container and the second container can be placed in fluid communication with the third container and the fourth container, respectively, to promote mixing of the first component with the solvent in the third container to form a solution of the first component in the first container, and to promote mixing of the second component with the solvent in the fourth container to form a solution of the second component in the second container, wherein the first syringe is also configured to mix the solution of the first component with the solution of the second component to form a hydrogel-forming composition for forming a hydrogel tissue sealant.
[0136] In certain embodiments, any hydrogel-forming composition described herein and / or any hydrogel-forming composition prepared using any kit described herein is suitable for use in a method of treatment by surgery. In certain embodiments, such a method of treatment by surgery comprises delivering a hydrogel-forming composition to a tissue site and forming a hydrogel tissue sealant at the tissue site. In certain embodiments, the treatment by surgery is a lung biopsy procedure, and wherein the composition is used to prevent or reduce the risk of pneumothorax during or after a lung biopsy procedure, which can be a procedure in which any hydrogel-forming composition described herein is delivered to the patient's pleural cavity to form a hydrogel tissue sealant, through which a biopsy sample is obtained.
[0137] In certain embodiments, a kit for forming a hydrogel tissue sealant comprises: a first container comprising a first component, the first component comprising a cross-linking agent; a second container comprising a second component, the second component comprising a protein, preferably a protein selected from human serum albumin, recombinant human serum albumin and animal-derived albumin; and optionally, one or more additional containers comprising one or more solvents for dissolving the first component and the second component, preferably water.
[0138] According to certain embodiments, the hydrogel-forming composition as described above or prepared using the kit as described above may be used in a method of treatment by surgery.
[0139] Other advantages and novel features of the present invention will become apparent from the following detailed description of multiple non-limiting embodiments of the present invention when considered in conjunction with the accompanying drawings. In the event that this specification and the documents incorporated by reference include conflicting and / or inconsistent disclosures, this specification shall prevail. BRIEF DESCRIPTION OF THE DRAWINGS
[0140] Some non-limiting embodiments of the present invention will be described by way of example with reference to the accompanying drawings, which are schematic and are not intended to be drawn to scale. In the drawings, each identical or nearly identical component shown is generally represented by a single numeral. For clarity, where illustration is not necessarily required for one of ordinary skill in the art to understand the present invention, not every component is labeled in every drawing, nor is every component of every embodiment of the present invention shown. In the drawings:
[0141] Figure 1 Steps in one exemplary method for forming a hydrogel tissue sealant according to certain embodiments are shown;
[0142] Figure 2Ashows a schematic diagram of a syringe device configured for storing and / or mixing one or more components of a hydrogel-forming composition according to certain embodiments;
[0143] Figure 2B shows a schematic diagram of an injector device configured for delivering a hydrogel-forming composition to a tissue site according to certain embodiments;
[0144] Figure 3A According to some embodiments, Figure 2A A schematic cross-sectional view of the syringe device shown in;
[0145] Figure 3B According to some embodiments, Figure 2B A schematic cross-sectional view of the syringe device shown in;
[0146] Figure 4 Steps in one exemplary method for hydrating and delivering a hydrogel-forming composition according to certain embodiments are shown;
[0147] Figure 5A shows an X-ray image of a porcine lung model according to certain embodiments;
[0148] Figure 5B shows an X-ray image of a post-biopsy porcine lung model according to certain embodiments;
[0149] Fig. 6A An X-ray image showing coaxial insertion of a syringe needle to deliver a hydrogel tissue sealant to a porcine lung model according to certain embodiments;
[0150] Figure 6B shows an X-ray image of a porcine lung model with a hydrogel tissue sealant according to certain embodiments;
[0151] Fig. 7A An image showing a hydrogel tissue sealant adhered to the parietal pleura of a porcine lung model according to certain embodiments;
[0152] Figure 7B An image showing a hydrogel tissue sealant adhered to the parietal pleura and visceral pleura of a porcine lung model according to certain embodiments;
[0153] Fig. 8A According to some embodiments, Figure 2B Schematic diagram of a syringe device depicted in , which is inserted into the pleural cavity of a subject with its coaxial cannula and then deploys the hydrogel-forming composition contained in the syringe;
[0154] Figure 8B According to some embodiments, Fig. 8A A schematic diagram of a syringe device of the type shown in FIG. 1 , wherein a plunger is depressed for deploying a hydrogel-forming composition for delivery into a pleural cavity of a subject being treated and forming a hydrogel lung sealant in the pleural cavity of the subject being treated;
[0155] Figure 8C A schematic diagram of a biopsy needle according to some embodiments is shown. Figure 8B Insertion of a coaxial cannula of a syringe device;
[0156] Fig.9A shows a CT scan of a subject (Subject 5) performed three days after deployment of the hydrogel and subsequent lung biopsy procedure, according to certain embodiments;
[0157] Fig. 9B shows a CT scan of a control subject (Control Subject 9) performed immediately after a lung biopsy procedure, showing air embolism, according to certain embodiments;
[0158] Fig. 9C shows a CT scan of a control subject (control subject 10) performed immediately after a lung biopsy procedure, showing a pneumothorax, according to certain embodiments; and
[0159] Fig.9D Shown is a CT scan of a control subject (Control Subject 6) performed two days after a lung biopsy procedure, showing a pneumothorax, in accordance with certain embodiments. DETAILED DESCRIPTION
[0160] Compositions and methods related to hydrogel tissue sealants are generally described. In certain embodiments, a hydrogel-forming composition is provided in a dry form (e.g., as one or more powder mixtures) and comprises at least a cross-linking agent and a protein capable of being cross-linked with the cross-linking agent. A solvent (i.e., one or more solvents) capable of dissolving the cross-linking agent and the protein can be provided and used to dissolve the hydrogel-forming composition to promote cross-linking. A surfactant capable of stabilizing the hydrogel-forming composition, increasing the rate at which the protein dissolves in one or more solvents and / or preventing protein aggregation can also be added to one or more components of the powder mixture, or to one or more solvents. Although in certain embodiments, all components of the composition can be part of a single dry mixture (e.g., a powder mixture), in other embodiments that can cause increased stability and improved shelf life, the composition can be separated into two or more reactive components (e.g., two or more dry powder mixtures), wherein at least the first component and the second component comprise a component that reacts with one or more components of another component. Preferably, in such embodiments, the components of each component are substantially non-reactive with the other components of such components, so that reaction can be prevented until the components are dissolved in one or more suitable solvents (e.g., hydrates) and combined prior to or during use to enable them to react to form a hydrogel. In cases where the components are separated into components that are substantially non-reactive relative to the other components of such components, the components can be formulated and stored in a hydrated, flowable form as opposed to a dry, non-hydrated form. In many of the discussions and examples below, the composition is provided as two dry powder components prior to hydrating and mixing the components to form a cross-linked hydrogel tissue sealant, but as described above, other dry and flowable formulations are possible.
[0161] As an example, the crosslinking of the hydrogel tissue sealant can be initiated by combining a first component comprising a crosslinking agent with a second component comprising a protein. In certain embodiments, the surfactant can be part of the second component. The first component can also include, for example, an antioxidant (e.g., a first antioxidant), which can be selected to improve the stability of the crosslinking agent. The second component can also include a second antioxidant, which can be selected to improve the stability of the protein. As a result, compared with other conventional hydrogel-forming compositions, the hydrogel-forming composition can have both an improved shelf life and an enhanced storage capacity. For example, in some embodiments, the hydrogel-forming composition described herein can be stored at room temperature for a long period of time (e.g., three years or more) without freezing. Other advantages of the hydrogel-forming composition can include a shorter, adjustable gel time and an improved shelf life, both of which are further described in more detail below.
[0162] In certain embodiments, a multi-component (e.g., two-component, three-component, four-component) composition formulation can be used. In some embodiments, the first component comprises a bifunctionalized polyalkylene oxide cross-linking agent, and the second component comprises a protein (e.g., freeze-dried albumin) that can be cross-linked with the bifunctionalized polyalkylene oxide. In certain embodiments, the second component may also include a cross-linking initiator (e.g., a base or alkaline buffer, such as sodium carbonate) that initiates cross-linking of the cross-linking agent with the protein. In certain embodiments, as described above, both the first component and the second component can be provided and stored as a powdered mixture. The powdered mixture can be hydrated separately or simultaneously (e.g., with a solvent, such as water, a biocompatible organic solvent or an aqueous solution), and then combined (if hydrated separately) to form a hydrogel tissue sealant. In certain embodiments, the hydration solution that hydrates the first component (and / or the second component) may also include a radiopaque agent that allows the hydrogel tissue sealant to be, for example, visible to the spectrum. The hydration solution that hydrates the second component (and / or the first component) may include an anti-foaming additive, such as a poloxamer. In certain embodiments, antifoam additives can aid in the refolding of proteins upon hydration.
[0163] The hydrogel-forming composition can be used to bind or seal tissue in vivo. In certain non-limiting embodiments, for example, it can be particularly useful to use the hydrogel-forming composition as a pleural lung sealant to seal air or fluid from entering the pleural cavity. In some such embodiments, the hydrogel lung sealant can advantageously reduce the occurrence of complications during and / or after a lung biopsy procedure, such as pneumothorax. In certain embodiments, in addition to or instead of being used as a hydrogel tissue sealant, the compositions and methods described herein can also be used in a variety of other medical applications, such as postoperative adhesion barriers or wound dressing materials.
[0164] As used herein, the term "crosslinking" refers to a chemical reaction between two or more similar or dissimilar polymers, copolymers, oligomers and / or macromonomers that connects two or more similar or dissimilar polymers, copolymers, oligomers and / or macromonomers by forming at least one covalent bond and / or ionic bond between one or more polymers, copolymers, oligomers and / or macromonomers, or chain extension, thereby providing a longer chain of one or more polymers, copolymers, oligomers and / or macromonomers by forming at least one covalent bond and / or ionic bond.
[0165] Electrophilic crosslinkers
[0166] According to certain embodiments, the hydrogel-forming composition comprises an electrophilic biodegradable polymer. In certain embodiments, the electrophilic biodegradable polymer may be a synthetic or naturally occurring polymer that contains or is functionalized to contain one or more, and preferably two or more, reactive electrophilic groups. Many suitable electrophilic biodegradable polymers are known to those of ordinary skill in the art. In some embodiments, for example, particularly advantageous and preferred crosslinking agents for the hydrogel-forming composition include difunctionalized polyalkylene oxides. In certain embodiments, the difunctionalized polyalkylene oxide has a composition described by the formula:
[0167] G-LM-PEG-LM-G;
[0168] in:
[0169] PEG is polyethylene glycol;
[0170] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d- represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0171] Each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl.
[0172] According to certain embodiments, the cross-linking agent is a difunctional polyalkylene oxide of the formula:
[0173] G-LM-PEG-LM-G;
[0174] in:
[0175] PEG is polyethylene glycol;
[0176] Each LM is identical and is a bifunctional linking moiety represented by the formula: -C(O)-; -(CH 2 ) b -C(O)-, wherein b is an integer from 1 to 5; -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 2 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; -C(O)-O-(CH 2 ) d -OC(O)-, wherein d is an integer from 2 to 10; and -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-or-RC(O)-O-(CH 2 ) d -OC(O)- represented by an oligomeric diradical, wherein c is an integer from 2 to 10, d is an integer from 2 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0177] Each G is the same and is a leaving group selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl and trifluoroethanesulfonyl.
[0178] According to some embodiments, the hydrogel-forming composition comprises any of a variety of suitable cross-linking agents (e.g., difunctionalized polyalkylene oxide). In some embodiments, the cross-linking agent is or comprises the following:
[0179] 2-arm PEG disuccinimidyl succinate (PEG(SS)) having the form 2 ):
[0180]
[0181] In certain embodiments, the cross-linking agent is or comprises:
[0182] 2-Arm PEG carboxymethyl esters having the following form:
[0183]
[0184] According to certain embodiments, the cross-linking agent (e.g., a difunctionalized polyalkylene oxide) of the formula G-LM-PEG-LM-G may have any of a variety of suitable weight average molecular weights. For example, in certain embodiments, the degree of ethoxylation in PEG (and the value of n in the above formula) is such that the weight average molecular weight of the cross-linking agent may be greater than or equal to 1 kDa, greater than or equal to 2 kDa, greater than or equal to 3 kDa, greater than or equal to 4 kDa, greater than or equal to 5 kDa, greater than or equal to 10 kDa, or greater than or equal to 15 kDa. In certain embodiments, the weight average molecular weight of the cross-linking agent may be less than or equal to 20 kDa, less than or equal to 15 kDa, less than or equal to 10 kDa, less than or equal to 5 kDa, less than or equal to 4 kDa, less than or equal to 3 kDa, or less than or equal to 2 kDa. Combinations of the above-described ranges are also possible (e.g., the weight average molecular weight of the cross-linking agent may be greater than or equal to 1 kDa and less than or equal to 20 kDa, and the weight average molecular weight of the cross-linking agent may be greater than or equal to 3 kDa and less than or equal to 5 kDa). Other ranges are also possible. In certain embodiments, for the formulas shown above for 2-arm PEG disuccinimidyl succinate and 2-arm PEG carboxymethyl ester, n is in the range of 10 to 500, more preferably 50 to 200. In some embodiments, the weight average molecular weight of the cross-linker is determined using size exclusion chromatography-multi-angle laser light scattering (SEC-MALLS).
[0185] According to certain embodiments, the difunctionalized polyalkylene oxide crosslinker described by the formula G-LM-PEG-LM-G, such as but not limited to the above examples, can be prepared by any of a variety of suitable synthetic methods known to those skilled in the art. See, for example, U.S. Pat. No. 6,576,263, U.S. Pat. No. RE38,827, and U.S. Pat. No. RE38,158, each of which is incorporated herein by reference in its entirety.
[0186] In some embodiments, the difunctionalized polyalkylene oxide described by the formula G-LM-PEG-LM-G can be prepared using known processes, procedures or synthetic methods, such as the procedures reported in U.S. Pat. No. 4,101,380 or U.S. Pat. No. 4,839,345, the procedures reported in International Application Serial No. PCT / US90 / 02133 filed on April 19, 1990, or the procedures reported by Abuchowski et al., Cancer Biochem. Biophys., 7:175-186 (1984), each of which is incorporated herein by reference in its entirety. Briefly, in certain embodiments, a polyalkylene oxide-based compound (e.g., polyethylene glycol discussed as an example below) and a suitable anhydride are dissolved in a suitable polar organic solvent in the presence of a base and refluxed for a period of time sufficient to form a polyethylene glycol diester diacid. The diester diacid is then reacted with a leaving group such as an N-hydroxyimide compound in the presence of dicyclohexylcarbodiimide or another condensing agent in a suitable polar organic solvent and stirred at room temperature to form the desired bifunctional crosslinker.
[0187] All or some of the difunctionalized polyalkylene oxide-based compounds that can be described by the formula G-LM-PEG-LM-G can be purchased from commercial sources, including but not limited to NOF America Corporation, Laysan Bio, Inc, Sigma-Aldrich and / or JenKem Technology USA. Given the teachings and exemplary methods described herein for exemplary compositions, published literature, and the level of ordinary technicians and the knowledge of the technician, those of ordinary skill in the art of chemical synthesis can also readily synthesize difunctionalized polyalkylene oxide-based compounds.
[0188] In certain non-limiting embodiments, PEG(SS) 2 It can be synthesized by obtaining a linear PEG with an average weight average molecular weight of 3,350 Da, equivalent to 75.7 ethylene oxide repeating units. Linear PEG can be obtained, for example, from Dow Chemical Company. In some embodiments, linear PEG can be converted to PEG(SS) by a two-step synthesis: 2 For example, in some examples, the first step can include reacting a linear PEG with two equivalents of succinic anhydride to form an ester. The second step can include reacting the ester with two equivalents of N-hydroxysuccinimide (NHS) to produce a crosslinker PEG(SS). 2 , yielding a white solid of a 2-arm cross-linker having two succinimidyl groups per molecule.
[0189] In certain embodiments, the difunctionalized polyalkylene oxide-based compound of formula G-LM-PEG-LM-G comprises a leaving group G (e.g., N-oxysuccinimidyl, N-oxymaleimido, N-oxyphthalimido, nitrophenoxy, N-oxyimidazole, and trifluoroethanesulfonyl). In such embodiments, the leaving group G is an electrophilic leaving group capable of reacting with a nucleophilic group such as an amine group of a protein. According to certain embodiments, the leaving group G reacts with an amine group of a nucleophile (e.g., a protein) to produce a cross-linked composition by forming an amide bond when the leaving group G is released. Such reactivity is further described in U.S. Patent No. 6,458,147, which is incorporated herein by reference in its entirety.
[0190] According to certain embodiments, the purity of the difunctionalized polyalkylene oxide crosslinker can be determined by its percentage difunctionality. A high percentage of difunctionality can advantageously result in a higher degree of crosslinking and / or crosslinking rate to provide a hydrogel formed by a hydrogel-forming composition having the following enhanced performance characteristics: for example, a fast gel time, a longer pot life and / or a longer shelf life, and / or improved mechanical properties or resorption time, each of which is described in more detail below. In some embodiments, the percentage difunctionality of the difunctionalized polyalkylene oxide crosslinker is greater than or equal to 75 wt.%, greater than or equal to 80 wt.%, greater than or equal to 85 wt.%, greater than or equal to 90 wt.%, greater than or equal to 95 wt.%, or greater than or equal to 99 wt.%. In certain embodiments, the percentage difunctionality of the difunctionalized polyalkylene oxide crosslinker is 70 wt.% to 99.9 wt.%, or 90 wt.% to 95%. Other ranges are also possible. As used herein, the percent difunctionality of a difunctional polyalkylene oxide crosslinker is determined by high-performance liquid chromatography (HPLC).
[0191] In powdered form, the difunctional polyalkylene oxide crosslinker can have a relatively low weight percent moisture content. The low weight percent moisture content of the powdered difunctional polyalkylene oxide crosslinker can advantageously provide a hydrogel-forming composition with an improved shelf life because the hydrolysis of the difunctional polyalkylene oxide is reduced, thereby maintaining the reactivity of the crosslinker over the storage time. In certain embodiments, for example, the weight percent moisture content of the powdered difunctional polyalkylene oxide crosslinker can be less than or equal to 10 wt.%, less than or equal to 9 wt.%, less than or equal to 8 wt.%, less than or equal to 7 wt.%, less than or equal to 6 wt.%, less than or equal to 5 wt.%, less than or equal to 4 wt.%, less than or equal to 3 wt.%, or less than or equal to 2 wt.%, based on the total weight of the powdered difunctional polyalkylene oxide crosslinker. In certain embodiments, the weight percent moisture content of the powdered crosslinking agent can be 1 wt.% to 10 wt.% based on the total weight of the powdered bifunctional polyalkylene oxide crosslinking agent, or 4 wt.% to 6 wt.% based on the total weight of the powdered bifunctional polyalkylene oxide crosslinking agent. Other ranges are also possible. The weight percent moisture content as described herein is determined using a moisture analyzer and / or Karl-Fischer titration.
[0192] According to certain embodiments, the hydrogel-forming composition comprises a powdered cross-linking agent in any of a variety of suitable amounts in a weight percentage (wt.%) by mass relative to the total weight of the powdered hydrogel-forming composition. For example, in some embodiments, the hydrogel-forming composition comprises a cross-linking agent in an amount based on the powder: greater than or equal to 10 wt.%, greater than or equal to 15 wt.%, greater than or equal to 20 wt.%, greater than or equal to 25 wt.%, greater than or equal to 30 wt.%, greater than or equal to 35 wt.%, greater than or equal to 40 wt.%, greater than or equal to 45 wt.%, greater than or equal to 50 wt.%, or greater than or equal to 55 wt.% of the total weight of the powdered hydrogel-forming composition. In certain embodiments, the hydrogel-forming composition comprises the following amount of crosslinking agent based on the powder: less than or equal to 60 wt.%, less than or equal to 55 wt.%, less than or equal to 50 wt.%, less than or equal to 45 wt.%, less than or equal to 40 wt.%, less than or equal to 35 wt.%, less than or equal to 30 wt.%, less than or equal to 25 wt.%, less than or equal to 20 wt.%, or less than or equal to 15 wt.%. Combinations of the above-recited ranges are also possible (e.g., the hydrogel-forming composition comprises the following amount of crosslinking agent based on the powder: greater than or equal to 10 wt.% and less than or equal to 60 wt.% of the total weight of the powdered hydrogel-forming composition; the hydrogel-forming composition comprises the following amount of crosslinking agent based on the powder: greater than or equal to 25 wt.% and less than or equal to 30 wt.% of the total weight of the powdered hydrogel-forming composition). Other ranges are also possible.
[0193] Nucleophilic biodegradable polymers such as proteins
[0194] In certain embodiments, the hydrogel-forming composition comprises a nucleophilic biodegradable polymer capable of crosslinking with an electrophilic biodegradable polymer. In certain embodiments, the nucleophilic biodegradable polymer may be a synthetic or naturally occurring polymer that contains or is functionalized to contain one or more, and preferably two or more reactive nucleophilic groups. Many suitable nucleophilic biodegradable polymers are known to those of ordinary skill in the art. In some embodiments, for example, particularly advantageous and preferred nucleophilic biodegradable polymers are proteins. According to some embodiments, for example, the hydrogel-forming composition comprises a nucleophilic biodegradable polymer capable of crosslinking with the above-mentioned electrophilic crosslinking agent (e.g., PEG(SS) 2) cross-linked proteins. In certain embodiments, the protein includes serum albumin (SA). In some embodiments, serum albumin can be human serum albumin (HSA) derived from donor blood, recombinant human serum albumin (rHSA) expressed in yeast and / or rice, and / or animal-derived albumin, such as bovine serum albumin (BSA). According to certain embodiments, the protein (e.g., rHSA) can be lyophilized. According to some embodiments, as described below, lyophilization of the protein can advantageously prevent protein degradation and improve shelf life and / or dissolution time when dissolved in an aqueous solvent.
[0195] In certain non-limiting embodiments, the protein can be a Cohn analog culture grade BSA obtained from Proliant Biologicals. In some embodiments, the recombinant human serum albumin can be Cellastim recombinant human serum albumin, Healthgen recombinant human serum albumin, Optibumin recombinant human serum albumin, InVitria human serum albumin, or Albumedix human serum albumin.
[0196] In certain embodiments, the protein can be or include collagen or gelatin. Other proteins are also possible.
[0197] According to certain embodiments, the purity and / or amount of the protein aggregates can be determined by the percentage of the monomer amount of the protein in the protein source. In certain embodiments, for example, the protein may contain greater than or equal to 60 wt.% protein monomers, greater than or equal to 65 wt.% protein monomers, greater than or equal to 70 wt.% protein monomers, greater than or equal to 75 wt.% protein monomers, greater than or equal to 80 wt.% protein monomers, greater than or equal to 85 wt.% protein monomers, greater than or equal to 90 wt.% protein monomers, or greater than or equal to 95 wt.% protein monomers. In certain embodiments, the protein contains less than or equal to 99 wt.% protein monomers, less than or equal to 95 wt.% protein monomers, less than or equal to 90 wt.% protein monomers, less than or equal to 85 wt.% protein monomers, less than or equal to 80 wt.% protein monomers, less than or equal to 75 wt.% protein monomers, less than or equal to 70% protein monomers, less than or equal to 70 wt.% protein monomers, or less than or equal to 65 wt.% protein monomers. Combinations of the above-recited ranges are also possible (e.g., the protein comprises greater than or equal to 60 wt.% protein monomers and less than or equal to 99 wt.% protein monomers, the protein comprises greater than or equal to 90 wt.% protein monomers and less than or equal to 95 wt.% protein monomers). Other ranges are also possible. As described in further detail below, certain components of the hydrogel-forming composition (e.g., surfactants and / or defoaming agents) can function to prevent aggregation and / or formation of protein dimers or higher multimeric structures.
[0198] Powdered protein can have a relatively low weight percent moisture content. In certain embodiments, for example, the weight percent moisture content of the powdered protein component can be greater than or equal to 1 wt.%, greater than or equal to 2 wt.%, greater than or equal to 3 wt.%, greater than or equal to 4 wt.%, greater than or equal to 5 wt.%, greater than or equal to 6 wt.%, greater than or equal to 7 wt.%, greater than or equal to 8 wt.%, or greater than or equal to 9 wt.%. In some embodiments, the weight percent moisture content of the powdered protein can be less than or equal to 10 wt.%, less than or equal to 9 wt.%, less than or equal to 8 wt.%, less than or equal to 7 wt.%, less than or equal to 6 wt.%, less than or equal to 5 wt.%, less than or equal to 4 wt.%, less than or equal to 3 wt.%, or less than or equal to 2 wt.% relative to the total weight of the powdered protein component. Combinations of the above-recited ranges are also possible (e.g., the percentage moisture content of the powdered protein can be greater than or equal to 1 wt.% to less than or equal to 10 wt.%, relative to the total weight of the powdered protein component, and the percentage moisture content of the powdered protein can be greater than or equal to 4 wt.% to less than or equal to 6 wt.%, relative to the total weight of the powdered protein component. Other ranges are also possible. As described herein, the weight percentage of moisture content is determined using a moisture analyzer and / or Karl-Fischer titration.
[0199] According to certain embodiments, the overall powdered hydrogel-forming composition comprises a protein (e.g., albumin) in any of a variety of suitable amounts of weight percentage (wt.%) by mass relative to the total weight of the powdered hydrogel-forming composition (i.e., based on the combined weight of the protein-containing powdered component and the electrophilic polymer-containing cross-linking agent powdered component). For example, in certain embodiments, the hydrogel-forming composition comprises the following amount of protein based on the powder: greater than or equal to 40 wt.%, greater than or equal to 45 wt.%, greater than or equal to 50 wt.%, greater than or equal to 55 wt.%, greater than or equal to 60 wt.%, greater than or equal to 65 wt.%, greater than or equal to 70 wt.%, or greater than or equal to 75 wt.%, based on the total weight of the powdered hydrogel-forming composition. In certain embodiments, the hydrogel-forming composition comprises the following amount of protein based on the powder: less than or equal to 80 wt.%, less than or equal to 75 wt.%, less than or equal to 70 wt.%, less than or equal to 65 wt.%, less than or equal to 60 wt.%, less than or equal to 55 wt.%, less than or equal to 50 wt.%, or less than or equal to 45 wt.%. Combinations of the above-recited ranges are also possible (e.g., the hydrogel-forming composition comprises the following amount of protein based on the powder: greater than or equal to 40 wt.% and less than or equal to 80 wt.% of the total weight of the powdered hydrogel-forming composition; the hydrogel-forming composition comprises the following amount of protein based on the powder: greater than or equal to 55 wt.% and less than or equal to 65 wt.% of the total weight of the powdered hydrogel-forming composition). Other ranges are also possible.
[0200] The ratio of the number of leaving groups G (e.g., NHS) to amine groups (e.g., amine groups of proteins) in the difunctionalized polyalkylene oxide-based compound of formula G-LM-PEG-LM-G can be any of a variety of suitable ratios. In certain embodiments, for example, the ratio of leaving groups G to amine groups is greater than or equal to 0.5:1, greater than or equal to 1:1, greater than or equal to 1.5:1, greater than or equal to 2:1, or greater than or equal to 2.5:1. In some embodiments, the ratio of leaving groups G to amine groups is less than or equal to 3:1, less than or equal to 2.5:1, less than or equal to 2:1, less than or equal to 1.5:1, or less than or equal to 1:1. Combinations of the above-described ranges are also possible (e.g., the ratio of leaving groups G to amine groups is greater than or equal to 0.5:1 and less than or equal to 3:1, and the ratio of leaving groups G to amine groups is greater than or equal to 2:1 and less than or equal to 2.5:1). Other ranges are also possible.
[0201] In certain non-limiting embodiments, the crosslinker is PEG(SS) 2 The protein is rHSA and PEG(SS)2 The ratio of NHS groups of rHSA to amine groups of rHSA is 2.21:1. In other non-limiting embodiments, the crosslinking agent is PEG(SS) 2 The protein is rHSA and PEG(SS) 2 The ratio of NHS groups to amine groups of rHSA is 2.65:1.
[0202] Crosslinking initiator
[0203] In some embodiments, the cross-linking reaction occurring between an electrophilic cross-linking agent and a nucleophile (e.g., a protein) is pH sensitive. In some such embodiments, for example, the cross-linking reaction is inhibited at an acidic pH and can be initiated and maintained by increasing the pH to a neutral or alkaline value. In some embodiments, the hydrogel-forming composition comprises a cross-linking initiator that initiates the cross-linking of a cross-linking agent and a nucleophile (e.g., a protein). In some embodiments, the cross-linking initiator can be combined with a protein as a powder mixture. In some such embodiments, the cross-linking initiator can be lyophilized with the protein.
[0204] In certain embodiments, the cross-linking initiator can be a base or alkaline buffer in some embodiments. In certain embodiments, for example, the cross-linking initiator comprises a base and / or alkaline buffer, which promotes the reaction between the leaving group G in the compound based on difunctionalized polyalkylene oxide of formula G-LM-PEG-LM-G and the amine group of protein. Any of a variety of suitable bases or alkaline buffers can be used. In certain embodiments in which the nucleophilic compound comprises an amine group reacted with the cross-linking agent, the alkaline cross-linking initiator is a base and / or alkaline buffer that does not include an amine functional group. In some embodiments, the alkali comprises carbonate (carbonate) and / or bicarbonate (bicarbonate) (for example, carbonate and / or bicarbonate). For example, in certain embodiments, the alkali or alkaline buffer comprises sodium carbonate. In some embodiments, the alkali or alkaline buffer comprises sodium bicarbonate. Other alkalis or alkaline buffers are possible.
[0205] The cross-linking reaction between the leaving group G and the amine group of the nucleophile (e.g., protein) can occur under any one of a variety of suitable pH values. In some embodiments, the cross-linking reaction is favorable under high pH values. In certain embodiments, for example, the cross-linking reaction between the leaving group G and the amine group of the nucleophile (e.g., protein) is initiated and occurs at the following pH: greater than or equal to 7, greater than or equal to 8, greater than or equal to 9, greater than or equal to 10, or greater than or equal to 11. In certain embodiments, the cross-linking reaction between the leaving group G and the amine group of the nucleophile is initiated and occurs at the following pH: less than or equal to 12, less than or equal to 11, less than or equal to 10, or less than or equal to 9. Combinations of the above-recited ranges are also possible (e.g., the cross-linking reaction between the leaving group G and the amine group of the nucleophile is initiated and occurs at a pH of greater than or equal to 7 to less than or equal to 11, the cross-linking reaction between the leaving group G and the amine group of the nucleophile is initiated and occurs at a pH of greater than or equal to 8 to less than or equal to 11, the cross-linking reaction between the leaving group G and the amine group of the nucleophile is initiated and occurs at a pH of greater than or equal to 9 to less than or equal to 11, or the cross-linking reaction between the leaving group G and the amine group of the nucleophile is initiated and occurs at a pH of greater than or equal to 10 to less than or equal to 11. Other ranges are also possible.
[0206] In certain non-limiting embodiments, the cross-linking reaction between the leaving group G and the amine group of the nucleophile (e.g., a protein) can be initiated to occur at a pH suitable for promoting the reaction by combining a cross-linker solution with a nucleophile solution, wherein the pH of the nucleophile solution is greater than or equal to 10.2 to less than or equal to 10.6.
[0207] The hydrogel-forming composition may include a powdered cross-linking initiator (e.g., a base or alkaline buffer) in any of a variety of suitable amounts in a weight percentage (wt.%) by mass based on the total weight of the powdered hydrogel-forming composition. The amount of the base or alkaline buffer may affect the reactivity of the hydrogel-forming composition, such as the gel time (described below), or other measures of the time required for the cross-linking agent to cross-link with a nucleophile (e.g., a protein). Therefore, in certain embodiments, it may be advantageous to select the type and / or amount of the base or alkaline buffer to promote the cross-linking rate and / or extent that enables the hydrogel to cross-link and form before or after the hydrogel-forming composition is delivered to a tissue site to effectively seal the tissue.
[0208] In certain embodiments, the hydrogel-forming composition comprises a cross-linking initiator in an amount based on the powder of greater than or equal to 0.1 wt.%, greater than or equal to 0.2 wt.%, greater than or equal to 0.5 wt.%, greater than or equal to 1 wt.%, greater than or equal to 1.5 wt.%, greater than or equal to 2 wt.%, greater than or equal to 2.5 wt.%, greater than or equal to 3 wt.%, greater than or equal to 4 wt.%, or greater than or equal to 5 wt.%, greater than or equal to 6 wt.%, greater than or equal to 7 wt.%, greater than or equal to 8 wt.%, or greater than or equal to 9 wt.%, based on the total weight of the powdered hydrogel-forming composition. In certain embodiments, the hydrogel-forming composition comprises a cross-linking initiator in the following amount based on the powder: less than or equal to 10 wt.%, less than or equal to 9 wt.%, less than or equal to 8 wt.%, less than or equal to 6 wt.%, less than or equal to 5 wt.%, less than or equal to 4 wt.%, less than or equal to 3 wt.%, less than or equal to 2 wt.%, less than or equal to 1.5 wt.%, less than or equal to 1 wt.%, less than or equal to 0.5 wt.%, or less than or equal to 0.2 wt.%, or less than or equal to 5 wt.%, based on the total weight of the powdered hydrogel-forming composition. Combinations of the above-recited ranges are also possible (e.g., the hydrogel-forming composition comprises the following amount of crosslinking initiator based on the powder: greater than or equal to 0.1 wt.% and less than or equal to 10 wt.%, or greater than or equal to 0.1 wt.% and less than or equal to 5 wt.% of the total weight of the powdered hydrogel-forming composition; the hydrogel-forming composition comprises the following amount of crosslinking initiator based on the powder: greater than or equal to 4 wt.% and less than or equal to 8 wt.% of the total weight of the composition). Other ranges are also possible.
[0209] According to certain embodiments, the cross-linking initiator can be divided into a part of the second component. For example, in some embodiments, the cross-linking initiator can be combined with a protein (e.g., albumin) as a powder mixture. In some such embodiments, the cross-linking initiator and the protein can be lyophilized. In some alternative embodiments, the cross-linking initiator can be dissolved in a solvent (e.g., water) and used as a hydration solution to hydrate the second component (e.g., protein).
[0210] Surfactants
[0211] In certain embodiments, the hydrogel-forming composition comprises a surfactant. In some embodiments, the surfactant can stabilize one or more components (e.g., the first component, the second component) of the hydrogel-forming composition. In certain embodiments, the surfactant can increase the dissolution rate of a protein (e.g., albumin) in one or more solvents used to dissolve the protein. In some embodiments, the surfactant can be selected to prevent aggregation (e.g., coagulation) of the protein (e.g., albumin).
[0212] Any of a variety of suitable surfactants can be used. In some embodiments, for example, the surfactant comprises non-functionalized polyethylene glycol (PEG). Any of a variety of non-functionalized PEGs can be used. In certain embodiments, the non-functionalized PEG is solid at room temperature. In certain embodiments, the weight average molecular weight of the non-functionalized PEG is, for example, greater than or equal to 100 g / mol and less than or equal to 40,000 g / mol. In certain embodiments, the non-functionalized PEG is PEG 8000 (e.g., a PEG having a molecular weight of 8000 g / mol). In certain embodiments, the surfactant comprises dextran sulfate. In some embodiments, the surfactant may comprise poloxamers, polysorbates (e.g., ), or encompass pure lipophilic substances, such as oils (e.g., mineral oils, vegetable oils), silicones, stearates, glycols and / or mixtures thereof. In certain embodiments, for example, poloxamer is L61. Other Poloxamer.
[0213] In some embodiments, the surfactant may additionally function as an antifoaming additive (although not all antifoaming additives need to be surfactants). The antifoaming additive may advantageously prevent foaming and / or bubble formation when the hydrogel-forming composition is hydrated to promote crosslinking. In some embodiments, for example, the antifoaming additive prevents the formation of bubbles that would otherwise be present in the hydrated hydrogel-forming composition if the antifoaming additive were not present. Such bubbles may disrupt crosslinking and weaken the hydrogel network of the resulting tissue sealant. In certain non-limiting embodiments, poloxamers (e.g., L61) is a defoaming additive.
[0214] According to certain embodiments, the hydrogel-forming composition comprises a powdered or liquid surfactant in any of a variety of amounts in weight percentage (wt.%) by mass relative to the total weight of the powdered or aqueous solution of the powdered hydrogel-forming composition. In some embodiments, for example, the hydrogel-forming composition comprises a surfactant in the following amount based on the powder or liquid: greater than or equal to 0.01 wt.%, greater than or equal to 0.1 wt.%, greater than or equal to 0.5 wt.%, greater than or equal to 1 wt.%, greater than or equal to 5 wt.%, greater than or equal to 10 wt.%, or greater than or equal to 15 wt.% of the total weight of the powdered or aqueous hydrogel-forming composition. In certain embodiments, the hydrogel-forming composition comprises the following amount of surfactant based on the powder or liquid: less than or equal to 20 wt.%, less than or equal to 15 wt.%, less than or equal to 10 wt.%, less than or equal to 5 wt.%, less than or equal to 1 wt.%, less than or equal to 0.5 wt.%, less than or equal to 0.1 wt.%, less than or equal to 0.01 wt.%. Combinations of the above-recited ranges are also possible (e.g., the hydrogel-forming composition comprises the following amount of surfactant based on the powder or liquid: greater than or equal to 1 wt.% and less than or equal to 30 wt.% of the total weight of the powder or aqueous hydrogel-forming composition; the hydrogel-forming composition comprises the following amount of surfactant based on the powder or liquid: greater than or equal to 10 wt.% and less than or equal to 20 wt.% of the total weight of the powder or aqueous solution of the powdered hydrogel-forming composition). Other ranges are also possible.
[0215] In some embodiments, the surfactant can be part of the second component. For example, in certain embodiments, the surfactant can be combined with the protein (and in some embodiments, the cross-linking initiator) as a powder mixture. In some such embodiments, the protein, cross-linking initiator, and surfactant can be lyophilized (e.g., before being dissolved in a solvent). Without wishing to be bound by theory, in some embodiments, the use of a liquid surfactant (e.g., In some embodiments of the present invention, the liquid surfactant can form hydrogen bonds with one or more powder components of the second component (e.g., protein). In some embodiments, the surfactant can be dissolved in a solvent (e.g., water) and / or mixed with a solvent (e.g., water) that is used as a hydration solution to hydrate the second component to form a hydrated solution that can crosslink with the first component when mixed with a solution of the first component. In certain embodiments, for example, the surfactant can be dispersed and / or suspended in a solvent for hydrating the second component.
[0216] According to certain embodiments, the hydrogel-forming composition may include more than one surfactant (e.g., two surfactants, three surfactants, etc.), wherein the cumulative amount of each individual surfactant, or all surfactants together, falls within any of the weight percentage ranges listed above.
[0217] Antioxidants
[0218] According to certain embodiments, the hydrogel-forming composition may include at least one antioxidant. Antioxidants can advantageously improve the storage stability of one or more components of the hydrogel-forming composition. For example, the use of one or more antioxidants can improve the shelf life and / or storage capacity of the hydrogel-forming composition. Because the one or more antioxidants are more susceptible to oxidation than the cross-linking agent used to form the hydrogel (e.g., due to a lower oxidation potential), the antioxidant is oxidized before the cross-linking agent during storage, which results in the hydrogel-forming composition having a longer shelf life than an otherwise comparable hydrogel-forming composition without the one or more antioxidants.
[0219] Any of a variety of suitable antioxidants can be used. In certain embodiments, for example, the composition comprises butylated hydroxytoluene (BHT). In some such embodiments, BHT prevents free radical-mediated oxidation. In certain embodiments, BHT can be used to prevent oxidation of cross-linking agents based on difunctionalized polyalkylene oxides. In some embodiments, the composition comprises N-acetyl-DL-tryptophan. In some such embodiments, N-acetyl-DL-tryptophan prevents oxidation of one or more amino acids and / or other residues of protein. In certain embodiments, the antioxidant is the following or comprises the following: butylated hydroxyanisole, butylated hydroxytoluene, propyl gallate d-alpha tocopheryl polyethylene glycol-1000 succinate, sodium pyrosulfite and / or a mixture thereof.
[0220] In some embodiments, the hydrogel-forming composition comprises at least two antioxidants. For example, in certain embodiments, the hydrogel-forming composition may comprise a first antioxidant (e.g., BHT) that prevents oxidation of a difunctionalized polyalkylene oxide-based crosslinker and a second antioxidant (e.g., N-acetyl-DL-tryptophan) that prevents oxidation of proteins.
[0221] In addition to preventing oxidation of one or more components of the hydrogel-forming composition, one or more antioxidants can in some cases stabilize one or more components of the hydrogel-forming composition (e.g., crosslinkers, proteins, etc.) to allow sterilization using a lethal dose of radiation (e.g., electron beam or gamma radiation). In certain embodiments, for example, one or more components of the hydrogel-forming composition (e.g., the first component and / or the second component) can be sterilized using electron beam radiation. In some such embodiments, one or more components of the hydrogel can be exposed to a cumulative dose of greater than or equal to 25 kGy to less than or equal to 30 kGy of electron beam radiation.
[0222] According to certain embodiments, the hydrogel-forming composition comprises each antioxidant (e.g., a first antioxidant, a second antioxidant) in any of a variety of suitable amounts of weight percentage (wt.%) by mass relative to the total weight of the powdered hydrogel-forming composition. In some embodiments, for example, the hydrogel-forming composition comprises each antioxidant in the following amount based on the powder: greater than or equal to 0.1 wt.%, greater than or equal to 1 wt.%, greater than or equal to 2 wt.%, greater than or equal to 5 wt.%, greater than or equal to 10 wt.%, or greater than or equal to 15 wt.%. In certain embodiments, the hydrogel-forming composition comprises each antioxidant in the following amount based on the powder: less than or equal to 20 wt.%, less than or equal to 15 wt.%, less than or equal to 10 wt.%, less than or equal to 5 wt.%, less than or equal to 2 wt.%, less than or equal to 1 wt.%, or less than or equal to 0.1 wt.% of the total weight of the powdered hydrogel-forming composition. Combinations of the above-recited ranges are also possible (e.g., the hydrogel-forming composition comprises the following amounts of each antioxidant based on the powder: greater than or equal to 0.1 wt.% and less than or equal to 20 wt.% of the total weight of the powdered hydrogel-forming composition; the hydrogel-forming composition comprises the following amounts of each antioxidant based on the powder: greater than or equal to 1 wt.% and less than or equal to 5 wt.% of the total weight of the powdered hydrogel-forming composition). Other ranges are also possible.
[0223] According to certain embodiments, antioxidant can be a part of the first component and / or the second component. In some embodiments, for example, at least one antioxidant can be combined with a cross-linking agent and / or protein as a powder mixture. In some such embodiments, antioxidant can be lyophilized together with protein (and / or cross-linking agent, in some cases). In certain alternative embodiments, antioxidant can be dissolved (for example, dissolved in a solvent such as water), which is used as a hydration solution to hydrate the first component and / or the second component.
[0224] Radiopaque agents
[0225] In some embodiments, the hydrogel-forming composition comprises a radiopaque agent. The use of a radiopaque agent can provide a resulting hydrogel with spectral imaging (e.g., imaging by X-ray or computed tomography (CT)). Any of a variety of suitable radiopaque agents can be added. In some embodiments, the radiopaque agent comprises gold (e.g., gold nanoparticles), silver (e.g., silver nanoparticles) or iodine. In certain embodiments, the radiopaque agent is potassium chloride (KCl), barium sulfate, iohexol or diatrizoate.
[0226] According to certain embodiments, the hydrogel-forming composition comprises any of a plurality of amounts of a radiopaque agent in a weight percentage (wt.%) by mass relative to the total weight of the powdered hydrogel-forming composition. In some embodiments, for example, the hydrogel-forming composition comprises a radiopaque agent in an amount based on the powder: greater than or equal to 0.1 wt.%, greater than or equal to 0.5 wt.%, greater than or equal to 1 wt.%, greater than or equal to 5 wt.%, greater than or equal to 10 wt.%, or greater than or equal to 15 wt.%. In certain embodiments, the hydrogel-forming composition comprises a radiopaque agent in an amount based on the powder: less than or equal to 20 wt.%, less than or equal to 15 wt.%, less than or equal to 10 wt.%, less than or equal to 5 wt.%, less than or equal to 1 wt.%, or less than or equal to 0.5 wt.% of the total weight of the powdered hydrogel-forming composition. Combinations of the above-recited ranges are also possible (e.g., the hydrogel-forming composition comprises the following amount of radiopaque agent based on the powder: greater than or equal to 0.1 wt.% and less than or equal to 20 wt.% of the total weight of the powdered hydrogel-forming composition; the hydrogel-forming composition comprises the following amount of radiopaque agent based on the powder: greater than or equal to 1 wt.% and less than or equal to 10 wt.% of the total weight of the powdered hydrogel-forming composition). Other ranges are also possible.
[0227] Other reagents
[0228] In any of the above embodiments, the hydrogel-forming composition may include additional active agents or ingredients for a variety of purposes, such as any of a variety of suitable active agents, such as antimicrobial agents, anti-inflammatory agents, hemostatic agents, and the like.
[0229] According to some embodiments, the hydrogel-forming composition is in the form of one or more powders (e.g., during storage of the hydrogel-forming composition). In certain embodiments, the one or more powders of the hydrogel-forming composition can be hydrated with water or one or more aqueous solutions to form an aqueous solution of the hydrogel-forming composition comprising a crosslinker, a protein, an optional surfactant, an optional antioxidant, and / or an optional crosslinking initiator. In certain embodiments, forming an aqueous solution of the hydrogel-forming composition comprising a crosslinker and a protein initiates crosslinking of the crosslinker with the protein, thereby forming a hydrogel tissue sealant.
[0230] As described above, in certain embodiments, hydrogel-forming compositions can be stored and / or provided as multi-component formulations, wherein certain ingredients are separated from other ingredients in different powdered or hydrated components. In some embodiments, for example, hydrogel-forming compositions at least include a first component, a second component, a solvent capable of dissolving the first component and the second component, and optionally a surfactant. In some such embodiments, the first component includes a cross-linking agent and an optional antioxidant, and the second component includes protein. In certain embodiments, the surfactant can be a part of the second component (e.g., a powder mixture with protein), or can be dissolved in a solvent and / or otherwise mixed with a solvent, and the solvent is used to hydrate the first component and / or the second component. In some embodiments, the hydrogel-forming composition includes a cross-linking initiator, which can be a part of the second component (e.g., a powder mixture with protein), or can be dissolved in a solvent for hydrating one or a component (e.g., the second component). In certain embodiments, for example, the second component is a mixture (e.g., a freeze-dried powder mixture) comprising protein, a cross-linking initiator and a surfactant. In some embodiments, the hydrogel-forming composition may further include at least one antioxidant, which may be part of the first component and / or the second component, or may be dissolved in the solvent used to hydrate the first component and / or the second component. In certain embodiments, the hydrogel-forming composition may further include a radiopaque agent, which may be part of the first component and / or the second component, or may be dissolved in the solvent used to hydrate the first component and / or the second component.
[0231] In certain embodiments, it may be advantageous to store the first component (e.g., which comprises a crosslinker (and optionally an antioxidant)) and the second component (e.g., which comprises a protein (and optionally a crosslinking initiator and / or a surfactant)) separately to avoid any crosslinking between the crosslinker and the protein during storage and / or to delay crosslinking until the hydrogel-forming composition is delivered to the tissue site. In certain embodiments, at least the second component (which comprises the protein, the crosslinking initiator, and the surfactant) may be lyophilized, or at least the protein of such component is lyophilized.
[0232] According to some embodiments, the first component may be in the form of a first powder mixture, and the second component may be in the form of a second powder mixture (e.g., during storage of the first component and / or the second component). In certain embodiments, the first component and / or the second component as a powder mixture may be solvated or hydrated (in the following description, "hydrated" is used for simplicity, but it should be understood that for some embodiments in which non-aqueous solvents are used, "solvated" should be replaced with "hydrated"), thereby providing a first component in the form of a first solution (e.g., a first aqueous solution) and a second component in the form of a second solution (e.g., a second aqueous solution). In certain embodiments, this may be advantageous: dissolving the first component (e.g., a cross-linking agent) in a biocompatible organic solvent such as DMSO to extend the pot life of the hydrogel-forming composition. In some embodiments, the hydrated first component and the hydrated second component may be combined to induce cross-linking of the cross-linking agent with the protein to form a hydrogel tissue sealant.
[0233] In certain embodiments, the first solution (e.g., the solution that hydrates the first component comprising the cross-linking agent) may include a radiopaque agent and / or a first antioxidant. In some embodiments, the second solution (e.g., the solution that hydrates the second component comprising the protein) may include a surfactant, a cross-linking initiator, and / or a second antioxidant.
[0234] When a protein is included as a nucleophilic polymer, the second component can be hydrated so that the concentration of the protein in the resulting hydrated solution is any one of a variety of suitable amounts. In some embodiments, for example, the concentration of the protein in the hydrated second component is greater than or equal to 10% by volume, greater than or equal to 15% by volume, greater than or equal to 20% by volume, greater than or equal to 25% by volume, or greater than or equal to 30% by volume. In certain embodiments, the concentration of the protein in the hydrated second component is less than or equal to 35% by volume, less than or equal to 30% by volume, less than or equal to 25% by volume, less than or equal to 20% by volume, or less than or equal to 15% by volume. Combinations of the above-described ranges are also possible (for example, the concentration of the protein in the hydrated second component is greater than or equal to 10% by volume and less than or equal to 35% by volume, and the concentration of the protein in the hydrated second component is greater than or equal to 20% by volume and less than or equal to 25% by volume). Other ranges are also possible.
[0235] According to certain embodiments, the lyophilized second component comprising a protein may have a relatively fast dissolution time. The term "dissolution time" used herein is given its ordinary meaning in the art and generally refers to the time required for the second component comprising a protein to completely dissolve when hydrated (or solvated) under mixing or stirring. A relatively fast dissolution time can advantageously reduce the time required to form a hydrogel tissue sealant. The dissolution time is calculated by starting a timer, hydrating the second component by mixing the second component with a hydrating solution, and stopping the timer when the second component is completely dissolved. In some embodiments, the dissolution time of the second component at 25°C may be greater than or equal to 10 seconds, greater than or equal to 15 seconds, greater than or equal to 20 seconds, greater than or equal to 25 seconds, greater than or equal to 30 seconds, or greater than or equal to 35 seconds. In certain embodiments, the dissolution time of the second component at 25°C is less than or equal to 40 seconds, less than or equal to 35 seconds, less than or equal to 30 seconds, less than or equal to 25 seconds, less than or equal to 20 seconds, or less than or equal to 15 seconds. Combinations of the recited ranges are also possible (e.g., the dissolution time of the second component at 25° C. is greater than or equal to 10 seconds to less than or equal to 40 seconds, the dissolution time of the second component at 25° C. is greater than or equal to 20 seconds to less than or equal to 30 seconds). Other ranges are also possible.
[0236] In certain embodiments, the dissolution time of the second component may depend on the amount of protein in the second component during hydration, that is, its mass by volume of the solution. For example, in some embodiments, the dissolution time of the second component is directly proportional to the amount of protein in the second component. In some non-limiting embodiments, for example, compared with a second component that is otherwise equal but has a relatively high amount of protein (for example, 30% by volume mass in the resulting hydration solution), a second component comprising a relatively low amount of protein (for example, 10% by volume mass in the resulting hydration solution) will have a shorter dissolution time, assuming that the final volume between the second component comprising the lower amount of protein is the same as that comprising the higher amount of protein.
[0237] The solution of the freeze-dried second component (e.g., comprising a protein and a cross-linking initiator) may have a relatively high pH when dissolved. In certain embodiments, for example, the pH of the solution of the freeze-dried second component after dissolution is greater than or equal to 9, greater than or equal to 9.5, greater than or equal to 10, or greater than or equal to 10.5. In some embodiments, the pH of the solution of the freeze-dried second component after dissolution is less than or equal to 11, less than or equal to 10.5, less than or equal to 10, or less than or equal to 9.5. Combinations of the above-described ranges are also possible (e.g., the pH of the solution of the freeze-dried second component after dissolution is greater than or equal to 9 to less than or equal to 11, and the pH of the solution of the freeze-dried second component after dissolution is greater than or equal to 10 to less than or equal to 10.5). Other ranges are also possible.
[0238] It should be understood that when specifying a second component, when hydrated as described herein, to produce a pH within the above ranges for the resulting solution, it is not necessary to specify the amount of protein added, as long as there is an amount of protein that can be hydrated to produce such a pH. That is, in some embodiments, even a relatively small amount of the second component (e.g., 10% by volume of mass) can be dissolved to produce a solution with a pH within the above ranges. For example, in some embodiments, the second component, when hydrated to form the resulting protein solution, produces a solution having a pH greater than or equal to 9, greater than or equal to 9.5, greater than or equal to 10, or greater than or equal to 10.5.
[0239] In certain embodiments, as described herein, the first component and the second component may be dissolved in one or more solvents, which are then combined / mixed together to form a cross-linked hydrogel-forming composition comprising a solution of the first component and the second component. In some embodiments, for example, the first component is dissolved in a first solvent and the second component is dissolved in a second solvent, which are then combined to form a hydrogel-forming composition solution. The pH of the hydrogel-forming composition solution of the first component and the second component may be less than or substantially similar to the pH of the solution of the lyophilized second component. In certain embodiments, for example, the pH of the cross-linked solution of the first component and the second component is greater than or equal to 7, greater than or equal to 8, greater than or equal to 9, greater than or equal to 9.5, greater than or equal to 10, or greater than or equal to 10.5. In some embodiments, the pH of the cross-linked solution of the first component and the second component is less than or equal to 11, less than or equal to 10.5, less than or equal to 10, or less than or equal to 9.5. Combinations of the above ranges are also possible (for example, the pH of the crosslinking solution of the first component and the second component is greater than or equal to 9 and less than or equal to 11, and the pH of the crosslinking solution of the first component and the second component is greater than or equal to 10 and less than or equal to 10.5). Other ranges are also possible.
[0240] In certain non-limiting but advantageous embodiments, the hydrogel-forming composition solution of the first component and the second component is formed by combining an unbuffered solution of the first component with a solution of the second component having a pH greater than or equal to 10.2 and less than or equal to 10.6.
[0241] The time required for the hydrated hydrogel-forming composition to crosslink and form a gel can determine how quickly the composition can act as a tissue sealant when the hydrogel / hydrogel-forming composition is delivered to a tissue site. This can be beneficial: when the hydrogel-forming composition is applied to a tissue site, the hydrogel-forming composition crosslinks within a sufficiently short time frame to allow the applied composition to quickly seal a tissue puncture site or other wound surface. As used herein, the "measured gel time" is determined by dispensing a hydrated first component and a hydrated second component into a vial containing a stir bar on a stir plate adjusted to 300 RPM, and recording the initial time (T) when the components of the composition are dispensed. 0 ), and then record the end time (T F ). The measured crosslinking time is the time when the timer stops minus the initial time. In certain embodiments, rheometry can be used to determine the measured gel time.
[0242] The hydrogel-forming composition may have any of a variety of suitable measured gel times for specific uses and application methods. In some embodiments, for example, the measured gel time of the hydrogel-forming composition may be greater than or equal to 0.1 seconds, greater than or equal to 0.5 seconds, greater than or equal to 1 second, greater than or equal to 2 seconds, greater than or equal to 3 seconds, greater than or equal to 4 seconds, greater than or equal to 5 seconds, greater than or equal to 10 seconds, or greater than or equal to 15 seconds. In certain embodiments, the measured gel time of the hydrogel-forming composition is less than or equal to 20 seconds, less than or equal to 15 seconds, less than or equal to 10 seconds, less than or equal to 5 seconds, less than or equal to 4 seconds, less than or equal to 3 seconds, less than or equal to 2 seconds, less than or equal to 1 second, or less than or equal to 0.5 seconds. Combinations of the above-described ranges are also possible (e.g., the measured gel time of the hydrogel-forming composition may be greater than or equal to 0.1 seconds and less than or equal to 20 seconds, and the measured crosslinking time of the hydrogel-forming composition may be greater than or equal to 1 second and less than or equal to 3 seconds). Other ranges are also possible.
[0243] According to certain embodiments, the measured gel time can be advantageously shortened by adjusting the amount of the cross-linking initiator. In some embodiments, for example, sufficient cross-linking initiator is added to provide a suitable pH value, as described herein, to initiate a cross-linking reaction between the cross-linking agent and the protein in a given surgical environment. In certain embodiments, the cross-linking initiator provides a pH value greater than or equal to 10 (e.g., 10.2 to 10.6, 10.3 to 10.4), which promotes a faster cross-linking reaction because the reaction is generally favorable at a higher pH value. In certain embodiments, the gel time is adjustable, depending on the amount of the base or alkaline buffer in the hydrogel-forming composition.
[0244] In some cases, it can be advantageous that the hydrogel-forming composition has a sufficiently long measured pot life. The term "measured pot life" as used herein refers to the duration of time that the hydrated first and second components of the hydrogel-forming composition remain usable after one or more powdered reactive components (e.g., first and / or second components) are hydrated but before the solutions of the first and second components are combined to form a cross-linked hydrogel-forming composition solution. In some embodiments, a sufficiently long pot life can advantageously allow the hydrated first and second components of the hydrogel-forming composition to remain usable after the user (e.g., physician) hydrates the first and second components until the user is ready to deliver one or more components to the application site to form a hydrogel tissue sealant. The "measured pot life" used herein is determined by measuring certain performance metrics, such as, for example, gel time and / or burst strength of the cross-linked hydrogel-forming composition or the formed hydrogel (both of which are described in more detail herein); and compared with the formed hydrogel or equivalent hydrogel-forming composition formed by the freshly hydrated first and second components of the hydrogel-forming composition without storage or delayed use after hydration. The measured pot life is the time required for a property metric of a cross-linked hydrogel composition produced from one or more hydrated components that have been stored for a period of time to differ from a property metric of a cross-linked hydrogel composition produced from one or more freshly hydrated components by a defined percentage (e.g., + / - 10%) of a clinically based minimum value for each property metric to ensure that the hydrogel tissue sealant can safely perform its function (e.g., seal tissue).
[0245] The hydrogel-forming component of the composition may have any of a variety of suitable pot life times (defined as performance metrics that vary by no more than + / - 10%). In some embodiments, for example, the pot life of the hydrogel-forming composition is greater than or equal to 10 minutes, greater than or equal to 20 minutes, greater than or equal to 30 minutes, greater than or equal to 1 hour, greater than or equal to 2 hours, greater than or equal to 5 hours, or greater than or equal to 10 hours. In certain embodiments, the pot life of the hydrogel-forming composition is less than or equal to 24 hours, less than or equal to 10 hours, less than or equal to 5 hours, less than or equal to 2 hours, less than or equal to 1 hour, less than or equal to 30 minutes, or less than or equal to 20 minutes. Combinations of the above-recorded ranges are also possible (e.g., the pot life of the hydrogel-forming composition is greater than or equal to 10 minutes to less than or equal to 24 hours, and the pot life of the hydrogel-forming composition is greater than or equal to 1 hour to less than or equal to 2 hours). Other ranges are also possible.
[0246] According to certain non-limiting embodiments, the shelf life of one or both reagent components of the hydrogel-forming composition can be improved by dissolving such components in a biocompatible non-polar organic solvent (e.g., DMSO) to form a solvated component of the hydrogel-forming composition, particularly for some embodiments in which the components are provided in solvated form. In some cases, the use of such a solvent can significantly increase the shelf life, for example, to greater than or equal to 1 week, greater than or equal to 1 month, greater than or equal to 6 months, greater than or equal to 1 year, or greater than or equal to 2 years.
[0247] According to some embodiments, it may be advantageous that the hydrogel-forming composition has a sufficiently long measured shelf life. The term "measured shelf life" as used herein refers to the duration that one or more powdered components of the hydrogel-forming composition remain suitably usable after storage of the one or more powdered components. In some embodiments, a sufficiently long shelf life may advantageously allow the hydrogel-forming composition to remain usable after long-term storage of the hydrogel-forming composition. The "measured shelf life" as used herein is determined by measuring certain performance metrics, such as, for example, the gel time, dissolution time and / or rupture strength (described in more detail herein) of a cross-linked hydrogel-forming composition solution that has undergone a storage period and / or a cross-linked hydrogel composition formed therefrom, compared to the corresponding measured metrics generated by such one or more powdered components (e.g., the first component and / or the second component) of the hydrogel-forming composition that has not been stored prior to hydration. The shelf life is measured as the time required for a property metric of a cross-linked hydrogel composition produced from one or more powdered components that have been stored for a period of time prior to hydration to differ from the same metric measured for the fresh component by a specified percentage (e.g., + / - 10%) of the clinically based minimum value for each property metric to ensure that the hydrogel tissue sealant can safely perform its function (e.g., seal tissue).
[0248] The first component and the second component of the hydrogel-forming composition can have any of a variety of suitable shelf life times. In some embodiments, for example, the shelf life of the hydrogel-forming composition (defined as a difference of + / - 10% compared to the fresh component) is greater than or equal to 1 week, greater than or equal to 1 month, greater than or equal to 6 months, greater than or equal to 1 year, greater than or equal to 2 years, greater than or equal to 3 years, or greater than or equal to 4 years. In certain embodiments, the shelf life of the hydrogel-forming composition is less than or equal to 5 years, less than or equal to 4 years, less than or equal to 3 years, less than or equal to 2 years, less than or equal to 1 year, less than or equal to 6 months, or less than or equal to 1 month. Combinations of the above-recited ranges are also possible (e.g., the shelf life of the hydrogel-forming composition is greater than or equal to 1 week to less than or equal to 5 years, the shelf life of the hydrogel-forming composition is greater than or equal to 1 year and less than or equal to 2 years). Other ranges are also possible.
[0249] A method of forming a hydrogel tissue sealant is provided. In some embodiments, the method comprises forming a crosslinking solution comprising at least a crosslinking agent and a nucleophilic biodegradable polymer (e.g., a protein), wherein forming the crosslinking solution initiates crosslinking of the crosslinking agent with the nucleophilic biodegradable polymer (e.g., a protein), thereby forming the hydrogel tissue sealant. In certain embodiments, as described herein, the crosslinking solution comprises a crosslinking initiator, a surfactant, and / or an antioxidant.
[0250] According to certain embodiments, the method of forming a hydrogel tissue sealant includes dissolving a first powdered component comprising a crosslinker (e.g., an electrophilic biodegradable polymer) and a second powdered component comprising a nucleophilic biodegradable polymer (e.g., a protein) in one or more solvents. In some embodiments, for example, the first component is dissolved in a first solvent (e.g., water or an aqueous solution) and the second component is dissolved in a second solvent (e.g., water or an aqueous solution). In some such embodiments, the dissolved first component and the dissolved second component are combined to form a crosslinked hydrogel-forming composition in the form of a solution comprising a crosslinker and a protein, thereby initiating crosslinking of the crosslinker with the nucleophilic biodegradable polymer (e.g., a protein) to form a hydrogel tissue sealant.
[0251] In certain embodiments, a method of forming a hydrogel tissue sealant comprises hydrating a first powdered component comprising a cross-linking agent and at least one antioxidant, hydrating a second powdered component comprising a protein, a cross-linking initiator, and a surfactant, and combining the hydrated first component and the hydrated second component to initiate cross-linking of the cross-linking agent and the protein. Figure 1Steps in such an exemplary method for forming a hydrogel tissue sealant are shown. Method 150, in step 152, includes hydrating a first powdered component comprising, for example, a cross-linking agent. In some embodiments, the first powdered component optionally comprises an antioxidant. In certain embodiments, the first powdered component is hydrated with a first solvent comprising water or a first aqueous solution. In some embodiments, the first solvent may comprise a radiopaque agent. Step 154 includes hydrating a second powdered component comprising, for example, a protein. In certain embodiments, the second powdered component comprises a cross-linking initiator and / or a surfactant. In some embodiments, the second powdered component is hydrated with a second solvent comprising water or a second aqueous solution. In certain embodiments, the second solvent comprises a defoaming agent. According to certain embodiments, steps 152 and 154 may occur simultaneously (but in separate containers). Step 156 includes combining the hydrated first component and the hydrated second component to initiate cross-linking of the cross-linking agent with the protein to form a hydrogel tissue sealant.
[0252] Also disclosed herein are methods related to sealing tissues with the formed hydrogel compositions. In some embodiments, for example, such methods include delivering a hydrogel-forming composition comprising a first component and a second component to a tissue site, or delivering a partially or fully crosslinked hydrogel composition to a tissue site, wherein the hydrogel composition comprises the reaction product of the first component and the second component reagents described above.
[0253] The hydrogel composition can be delivered to the tissue site in any of a variety of suitable ways. In some embodiments, the first component of the hydrogel-forming composition and the second component of the hydrogel-forming composition can be at least partially combined to induce crosslinking before the hydrogel composition is delivered to the tissue site. In certain embodiments, the first component of the hydrogel-forming composition and the second component of the hydrogel-forming composition are completely combined before the hydrogel composition is delivered to the tissue site. According to certain embodiments, the hydrated first component of the hydrogel-forming composition and the hydrated second component of the hydrogel-forming composition can be crosslinked when the hydrogel composition is delivered to the tissue site. In some embodiments, for example, the hydrogel tissue sealant is at least partially formed before or after being delivered to the tissue site. In certain embodiments, the tissue site is a pleural site, such as the parietal pleura and / or the visceral pleura.
[0254] In certain embodiments, one or more syringes, sprayers or other applicators can be used to deliver hydrogel-forming compositions to tissue sites. In certain embodiments, for example, an applicator that can be used to deliver hydrogel-forming compositions is described in U.S. Patent Application Serial No. 62 / 822,490 entitled "LUNG BIOPSY FLOWABLE SEALANT DELIVERY SYSTEM" or PCT / US2020 / 023772 entitled "SEALANT DELIVERY APPARATUS, AND SYSTEM AND METHOD FOR PREPARING SAME, FOR USE IN ALUNG PROCEDURE", both of which are incorporated herein by reference as a whole. The following applications submitted on the same day as this article are also incorporated by reference as a whole: International Application No. PCT / US21 / 23171 entitled "MULTI-COMPONENT SEALANT DELIVERY SYSTEMS INCORPORATION QUARTER TURN CONNECTORS" submitted on March 19, 2021. Additional details regarding the hydrogel-forming composition delivery device are described below.
[0255] According to some embodiments, the hydrogel tissue sealant can be formulated to adhere to the tissue site. In certain embodiments, the adhesion of the hydrogel tissue sealant at the tissue site can be determined by a liquid rupture pressure strength model based on ASTM F2392-04 (Standard Test Method for Burst Strength of Surgical Sealants). According to some embodiments, the test is designed to determine the pressure required to rupture the sealant patch covering the simulated liquid leakage, and indirectly measure the adhesive properties of the sealant to the simulated tissue. In certain embodiments, the hydrogel tissue sealant may have any of a variety of suitable rupture pressure strengths (e.g., liquid rupture pressure strength). For example, in some embodiments, the rupture pressure strength of the hydrogel tissue sealant measured by such a test is greater than or equal to 10 mm Hg, greater than or equal to 50 mm Hg, greater than or equal to 100 mm Hg, greater than or equal to 150 mm Hg, greater than or equal to 200 mm Hg, or greater than or equal to 250 mm Hg. In certain embodiments, the burst pressure strength of the hydrogel tissue sealant measured by such a test is less than or equal to 300 mm Hg, less than or equal to 250 mm Hg, less than or equal to 200 mm Hg, less than or equal to 150 mm Hg, less than or equal to 100 mm Hg, less than or equal to 50 mm Hg. Combinations of these ranges are also possible (e.g., a hydrogel tissue sealant having a burst pressure strength of greater than or equal to 10 mm Hg and less than or equal to 300 mm Hg, a hydrogel tissue sealant having a burst pressure strength of greater than or equal to 100 mm Hg and less than or equal to 150 mm Hg). Other ranges are also possible.
[0256] In some embodiments, the cross-linked hydrogel tissue sealant may swell after delivery to the tissue site (e.g., in the presence of water). In some embodiments, advantageously, the hydrogel tissue sealant may have a relatively high swelling rate and / or swelling degree (characterized by an increase in mass after a defined swelling period). A hydrogel tissue sealant with a relatively high swelling rate may be advantageous because the hydrogel tissue sealant may swell and conform to the tissue delivery site to improve sealing properties. In certain embodiments, and as described in more detail below, the hydrogel composition may be delivered to the tissue site by a coaxial cannula. In certain embodiments, the coaxial cannula is surrounded by the hydrogel composition during and / or after the delivery of the hydrogel composition, so as to perform a biopsy operation (e.g., a lung biopsy). In some embodiments, the coaxial cannula may be removed through the body of the hydrogel after the biopsy operation, resulting in a puncture, void, or hole in the hydrogel tissue sealant. In some such embodiments, the hydrogel tissue sealant can swell (e.g., in the presence of water) after the coaxial cannula is removed, thereby substantially closing and / or filling the puncture, void, and / or hole caused by the coaxial cannula. The swelling rate of the hydrogel tissue sealant can be determined by forming a cross-linked hydrogel sealant as described herein, recording the weight of the hydrogel composition, incubating the hydrogel composition in a phosphate-buffered saline (PBS) solution at 37° C., removing the hydrogel composition from the PBS solution after two hours, and recording the weight of the hydrogel composition, wherein the percentage is calculated by the percentage increase in weight.
[0257] According to certain embodiments, the swelling mass increase of the hydrogel tissue sealant is greater than or equal to 30%, greater than or equal to 35%, greater than or equal to 40%, greater than or equal to 45%, greater than or equal to 50%, greater than or equal to 55%, greater than or equal to 60%, or greater than or equal to 65%. In some embodiments, the swelling mass increase of the hydrogel tissue sealant is less than or equal to 70%, less than or equal to 65%, less than or equal to 60%, less than or equal to 55%, less than or equal to 50%, less than or equal to 45%, less than or equal to 40%, or less than or equal to 35%. Combinations of the above-recited ranges are also possible (e.g., the swelling mass increase of the hydrogel tissue sealant is greater than or equal to 30% to less than or equal to 70%, and the swelling rate of the hydrogel tissue sealant is greater than or equal to 40% to less than or equal to 50%). Other ranges are also possible.
[0258] According to certain embodiments, the hydrogel tissue sealant can be used as a pleural lung sealant to seal air and / or fluid from entering the pleural cavity. In some embodiments, the hydrogel tissue sealant can be used to seal the pleura together.
[0259] The hydrogel tissue sealant may degrade over time in the subject. In certain embodiments, the degradation time of the hydrogel may be determined by a degradation model based on ASTM F1635 (Standard Test Method for inVitro Degradation). In some embodiments, the test is designed to determine the degradation rate (i.e., mass loss rate) and changes in material or structural properties of the material used for surgical implants, or both. The hydrogel tissue sealant may have any of a variety of suitable degradation times. In some embodiments, for example, the degradation time of the hydrogel tissue sealant is greater than or equal to 1 day, greater than or equal to 5 days, greater than or equal to 7 days, greater than or equal to 10 days, or greater than or equal to 15 days. In certain embodiments, the degradation time of the hydrogel tissue sealant is less than or equal to 20 days, less than or equal to 15 days, less than or equal to 10 days, less than or equal to 7 days, or less than or equal to 5 days. Combinations of the above-recited ranges are also possible (e.g., a degradation time of the hydrogel tissue sealant is greater than or equal to 1 day to less than or equal to 20 days, a degradation time of the hydrogel tissue sealant is greater than or equal to 10 days to less than or equal to 15 days). Other ranges are also possible.
[0260] According to certain embodiments, a kit is provided. The kit may include one or more devices, such as a container or a syringe comprising a container (e.g., a syringe barrel), which is capable of storing one or more components of the hydrogel-forming composition, mixing one or more components of the hydrogel-forming composition, and / or delivering the hydrogel-forming composition (or one or more components thereof) to a tissue site. For example, Figure 2A shows a schematic diagram of a dual syringe, 4 compartment / container device 200 capable of storing one or more components of a hydrogel-forming composition and / or mixing one or more components of a hydrogel-forming composition with one or more solvents, according to certain embodiments; and Figure 3A A cross section thereof is shown. Figure 2B According to some embodiments, Figure 2A A schematic diagram of an apparatus in which a second syringe assembly containing a hydrated / dissolved first component and a second component of a hydrogel-forming composition is connected to a coaxial cannula to enable delivery of the hydrogel-forming composition to a tissue site; and Figure 3B A cross section thereof is shown.
[0261] The kit may contain any of the above first components contained in a first container, such as Figures 2A to 3B As shown in , the first container may conveniently be the barrel of a syringe device. Figure 3A For example, a syringe device 200 (e.g., wherein two interconnected syringe components of the device are configured to mix stored components with one or more solvents) may include, for example, a first component containing a cross-linking agent contained within a first barrel / container 102 during storage. In certain embodiments, the first component may also include an antioxidant (e.g., BHT), a surfactant, and / or a radiopaque agent.
[0262] The first component may be in the form of a first dry powder.
[0263] The kit may further comprise a second container comprising any of the second components described above. Figure 3A For example, the syringe device 200 may include a second component in the second barrel / container 104, for example during storage. In some embodiments, the second component may include a protein capable of being cross-linked with a cross-linking agent. The second component may also include a cross-linking initiator and / or a surfactant (e.g., PEG 8000) that initiates cross-linking of the cross-linking agent with the protein. In some embodiments, the second component may also include a radiopaque agent. The second component may be in the form of a second dry powder.
[0264] In some embodiments, the kit further comprises a third component, such as a solvent component, contained in a third container. Figure 3A , the device 200 may include such a third component in the third cartridge / container 106. According to certain embodiments, the third component includes a first solvent (e.g., water, DMSO) or solution (e.g., aqueous solution) for dissolving and / or hydrating the first powdered component. In some embodiments, the first solvent or solution includes an antioxidant (e.g., BHT), a radiopaque agent (e.g., KCl) and / or a surfactant.
[0265] In certain embodiments, the kit further comprises a fourth component, such as a solvent component, contained in a fourth container. Figure 3A , the device 200 may include such a fourth component in the fourth cartridge container 108. According to some embodiments, the fourth compartment includes a second solvent (e.g., water, DMSO) or solution (e.g., aqueous solution) for dissolving and / or hydrating the second powdered component. In certain embodiments, the second solvent or solution includes a cross-linking initiator (e.g., a base or alkaline buffer, such as sodium carbonate). In some embodiments, the second solvent or solution includes an antioxidant (e.g., N-acetyl-DL-tryptophan), a radiopaque agent, or a surfactant (e.g., L61).
[0266] According to some embodiments, and as shown, one or more of the first, second, third, and fourth containers is a compartment (barrel) of a syringe or applicator. Figure 2A and 3A , the first barrel / container 102 and the second barrel / container 104 can be a first syringe 100 (e.g., also used as an applicator syringe in the disclosed embodiments, see Figure 2B ), while the third barrel / container 106 and the fourth barrel / container 108 are double barrels of a second syringe 120 (e.g., which contains a mixing or hydrating solvent).
[0267] According to certain embodiments, a kit for forming a hydrogel tissue sealant comprises one or more syringes that together provide at least three separate containers. In some embodiments, for example, the kit comprises a first container (e.g., first container 102 in first syringe 100) containing a first component (e.g., electrophilic biodegradable polymer) in powder form, a second container (e.g., second container 104 in first syringe 100) containing a second component (e.g., nucleophilic biodegradable polymer) in powder form, and at least a third container (e.g., third container 106 and fourth container 108 in second syringe 120) containing one or more solvents.
[0268] The kit may include one or more syringes (e.g., one syringe, two syringes, three syringes, four syringes). One or more syringes may have any of a variety of suitable configurations. In certain embodiments, for example, the kit includes two syringes (e.g., a first syringe 100 and a second syringe 120). In certain embodiments, each syringe in the one or more syringes may be a double-barreled syringe. In some embodiments, the first syringe 100 (e.g., an applicator syringe) may include a first container 102 containing a first component in powder form, and a second container 104 containing a second component in powder form. According to certain embodiments, the second syringe 120 (e.g., a mixing or hydration syringe) includes a third container 106 containing a first solvent capable of dissolving the first component, and a fourth container 108 containing a second solvent capable of dissolving the second component.
[0269] In some embodiments, one or more syringes (e.g., a first syringe 100 and a second syringe 120) are configured so that the first container 102 and the second container 104 can be placed in fluid communication with at least a third container 106 containing one or more solvents. Configuring the kit in this way promotes mixing of the first component with one or more solvents to form a solution of the first component, and promotes mixing of the second component with one or more solvents to form a solution of the second component. For example, in certain embodiments, the first syringe 100 (e.g., an applicator syringe) and the second syringe 120 (e.g., a mixing or hydration syringe) are configured to be fluidically connected to each other so that the first container 102 and the second container 104 can be placed in separate fluid communication with the third container 106 and the fourth container 108, respectively, to promote mixing of the first component with the first solvent to form a solution of the first component in the first container 102, and promote mixing of the second component with the second solvent to form a solution of the second component in the second container 104.
[0270] The kit may include one or more devices capable of delivering the hydrogel-forming composition (or one or more components thereof) to a tissue site. For example, Figure 2B shows a schematic diagram of a device capable of delivering a hydrogel-forming composition to a tissue site according to some embodiments, and Figure 3B Its cross section is shown. Figure 2B As shown in , the device 250 (e.g., a delivery device) comprises a first syringe 100 and a needle assembly. In some embodiments, the needle assembly comprises a coaxial cannula 130 and a needle 132. In some embodiments, the first syringe 100 is configured to mix and contain a dissolved first component (e.g., a solution of the first component) and a dissolved second component (e.g., a solution of the second component) to form a cross-linked solution of the first component and the second component, which is capable of forming a hydrogel tissue sealant after being delivered to a tissue site through the needle assembly.
[0271] Figure 4 According to some embodiments, a method for using Figures 2A to 3B A summary of the steps in an exemplary method of hydrating and delivering a hydrogel-forming composition using a device depicted in FIG. In some embodiments, method 400 of hydrating and delivering a hydrogel-forming composition includes step 402, wherein step 402 includes inserting an applicator syringe (e.g., Figure 2A and 3A The first syringe 100) and the mixing syringe (eg, Figure 2A and 3A In some such embodiments, the applicator syringe (e.g., Figure 2A and 3AThe first syringe 100 in the embodiment includes: a first container (eg, Figure 2A and 3A The first component contained in the first container 102) and the first component contained in the second container (e.g., Figure 2A and 3A a second component in a second container 104); a mixing syringe (e.g., Figure 2A and 3A The second syringe 120 in the embodiment includes: a third container (e.g., Figure 2A and 3A The third component contained in the third container 106 in the embodiment of the present invention, and the third component contained in the fourth container (e.g., Figure 2A and 3A A fourth component in a fourth container 108).
[0272] In certain embodiments, method 400 includes step 404, which includes sequentially depressing an applicator syringe (e.g., Figure 2A and 3A The first syringe 100) and the mixing syringe (e.g., Figure 2A and 3A The piston of the second syringe 120) is opened to allow the liquid contained in the first container (e.g., Figure 2A and 3A The first component contained in the first container 102) and the first component contained in the second container (e.g., Figure 2A and 3A Step 406 of method 400 includes evaluating whether the first component and / or the second component are fully hydrated (e.g., fully dissolved). If the first component and / or the second component are not fully hydrated, step 404 is repeated. If the first component and the second component are fully hydrated, the user may proceed to step 408.
[0273] According to some embodiments, step 408 of method 400 includes placing a mixing syringe (e.g., Figure 2A and 3A The second syringe 120 in the embodiment of the present invention is connected to the applicator syringe (e.g., Figure 2A and 3A Step 410 includes disconnecting the needle assembly (e.g., Figure 2B 130 and needle 132) connected to an applicator syringe (e.g., Figure 2B and 3B The first syringe 100 in FIG.
[0274] According to some embodiments, method 400 includes step 420, which includes injecting a material (e.g., a solution of a first component and a solution of a second component) from an applicator syringe (e.g., Figure 2B and 3B In some embodiments, deploying the material includes mixing a solution of the first component with a solution of the second component to form a cross-linked solution of the first component and the second component when the material is delivered to the tissue site (e.g., at one or more mixing points within the needle assembly, at the proximal end of the needle assembly, and / or at the distal end of the needle assembly).
[0275] According to certain embodiments, a needle assembly comprising a coaxial cannula is used to deliver a hydrogel composition and perform a biopsy procedure (e.g., a lung biopsy). In some embodiments, for example, device 250 (e.g., a delivery device) is used to insert a coaxial cannula into the pleural cavity of a subject so that the hydrogel-forming composition can be deployed at the tissue site. See, e.g., Fig. 8A , which shows a schematic diagram of a hydrogel delivery device according to certain embodiments, wherein a coaxial cannula of the hydrogel delivery device is inserted into the pleural cavity of a subject. The hydrated hydrogel-forming composition is deployed to the tissue site. See, e.g. Figure 8B , which shows a schematic diagram of a hydrogel delivery device according to certain embodiments, wherein the hydrogel delivery device deploys a hydrogel-forming composition through a coaxial cannula to provide a hydrogel tissue sealant at a tissue site. In some embodiments, the hydrogel-forming composition is deployed during or after the user pushes the cannula through the tissue site.
[0276] In some embodiments, a biopsy is performed after delivery of the hydrogel composition. For example, according to certain embodiments, the syringe assembly 100 of the device 250 is removed from the needle assembly comprising a coaxial cannula, and a biopsy device comprising a standard biopsy needle is inserted through the coaxial cannula. A biopsy (e.g., lung biopsy) procedure is then performed. See, e.g. Figure 8C , which shows a schematic diagram of a biopsy needle according to certain embodiments, which is inserted through a coaxial cannula to perform a biopsy procedure.
[0277] In certain embodiments, after the hydrogel composition is deployed at the tissue site to provide the hydrogel tissue sealant and the biopsy procedure is performed, the biopsy device and the needle assembly comprising the coaxial cannula are removed from the application site. According to some embodiments, as described herein, the hydrogel tissue sealant can swell (e.g., in the presence of water) to seal any punctures, voids, and / or holes in the hydrogel tissue sealant caused by the removal of the needle assembly.
[0278] During storage, in order to prevent the increase of moisture or oxygen absorption by the powdered ingredients, one or more containers / syringes containing one or more powdered components (especially the powdered first component (e.g., which contains a cross-linking agent)) can be placed in a sealed bag (e.g., a sealed foil bag), which is optionally flushed with an inert gas such as nitrogen or under an inert gas such as nitrogen atmosphere, and optionally also contains a desiccant material (e.g., a desiccant or molecular sieve material, such as containing (Mitsubishi Gas Chemical America, Inc.) or a desiccant package of 4A molecular sieve (Multisorb Filtration Group).
[0279] Example 1
[0280] The following example describes the use of a hydrogel tissue sealant in a porcine lung model. Figure 5A As shown, an X-ray image of a pig lung model was obtained. A biopsy was performed on the pig lung model. Figure 5B An image of normal airway pressure after biopsy of a porcine lung model is shown. A hydrogel-forming composition was prepared comprising PEG(SS) 2 and the reaction products of albumin and iohexol as a radiopaque substance. Fig. 6A As shown, the hydrogel-forming composition is delivered to a porcine lung model through a needle (circled) after initial puncture of the lung, and then a biopsy is performed. The hydrogel tissue sealant can be seen passing through the soft tissue and pleural cavity. The coaxial assembly of the applicator is left in place, and the sealant application needle is removed. A biopsy needle is inserted through the coaxial assembly into the target tissue, a biopsy sample is obtained, and the coaxial assembly and biopsy needle are removed. Figure 6B As shown, the hydrogel tissue sealant (circled) remains in place and is easily seen after the procedure, sealing the puncture site. The hydrogel tissue sealant allows for normal ventilation. Figure 5B An X-ray image of a pig lung model after biopsy is shown. Fig. 7A As shown, the hydrogel tissue sealant (circled) adhered to the parietal pleura of the porcine lung model. Figure 7B As shown, the hydrogel tissue sealant (circled) protrudes from the interior of the lung and adheres to the parietal and visceral pleura of a porcine lung model, thereby sealing the biopsy tract.
[0281] Example 2
[0282] The following examples describe the evaluation of the stability of hydrogel-forming compositions in accelerated aging studies.
[0283] According to Table 1, PEG(SS) is produced. 2Samples of hydrogel-forming compositions of a component containing PEG(SS) and a component containing recombinant human serum albumin (rHSA). 2 Obtained from Sigma (samples 1, 3, and 4) or Laysan Bio (sample 2) and processed under nitrogen. Contains PEG (SS) 2 The composition contains PEG(SS) 2 Or PEG(SS) with added BHT 2 In some cases, the bag also contains a desiccant or molecular sieve material - containing (Mitsubishi Gas Chemical America, Inc.) or 4A molecular sieve (Multisorb Filtration Group). 2 The component of the invention is aliquoted into a first syringe and stored in a sealed foil bag under a nitrogen atmosphere. The rHSA-containing component solution for preparing the rHSA-containing component for forming a hydrogel by lyophilization comprises rHSA obtained from InVitria (Junction City, KS), which is added with sodium carbonate and PEG 8000, combined with reverse osmosis (RO) water so that the concentration of rHSA is 30% by volume. The rHSA-containing component solution in RO water is lyophilized, ground into a powder, aliquoted into a second syringe, and sealed in a foil bag under a nitrogen environment.
[0284] Use deionized (DI) water in the third syringe (for hydrating the PEG(SS) 2 of components) and the fourth syringe contains L61 of DI water (for hydrating the lyophilized rHSA-containing components) to produce a hydration kit. The hydration kit was sealed in a foil bag with two A connector was to be attached to each syringe so that the powder mix could be hydrated upon use. The samples received two doses of e-beam sterilization. All samples were stored and conditioned at 40°C to simulate advanced aging compared to room temperature storage.
[0285] Table 1: Components of the hydrogel-forming compositions tested.
[0286]
[0287] The samples were aged according to Table 2, pulled at the indicated time points, and evaluated as described in further detail below.
[0288] Table 2: Stability time points of hydrogel-forming compositions and corresponding simulated high aging.
[0289] Stability time point Simulated high aging Zero Hour 0 113 days 1 year 225 days 2 years 338 days 3 years
[0290] The gel time of the four hydrogel-forming composition samples shown in Table 1 was evaluated at each stability time point by: (i) 2 The invention relates to the method of preparing a hydrated composition comprising the invention and the rHSA-containing composition, (ii) hydrating the composition comprising the rHSA-containing composition, (iii) waiting for a period of 2 minutes, 30 minutes or 60 minutes after hydration, (iv) dispensing the hydrated composition into vials containing a stir bar on a stir plate adjusted to 300 RPM, (iv) recording the initial time when dispensing the composition, and (v) recording the end time when the stir bar stops rotating due to gelation. The results are shown in Table 3.
[0291] Table 3: Gel time of the tested hydrogel-forming compositions for aged samples at the indicated stability time points (average of three replicate measurements).
[0292]
[0293]
[0294] * = Two out of three samples did not form a gel.
[0295] The dissolution times of the four rHSA-containing component samples shown in Table 1 were evaluated at each stability time point by: (i) mixing a syringe containing the rHSA-containing component with a syringe containing DI water and The syringe of L61 was connected, (ii) a timer was started, (iii) the fluid was repeatedly pushed into the powder syringe, and (iv) the timer was stopped when the rHSA-containing component was completely dissolved. The results are shown in Table 4.
[0296] Table 4: Dissolution times of rHSA-containing components of aged samples at the indicated stability time points (mean of three replicates).
[0297]
[0298] The pH of the four rHSA-containing component samples shown in Table 1 was evaluated at each stability time point by: (i) using a 5% ethanol solution containing DI water and The powder mixture was dissolved by syringe of L61 as described above for the dissolution time measurement, and (ii) the pH of the solution was measured using a calibrated Mettler Toledo FiveEasy pH meter. The results are shown in Table 5.
[0299] Table 5: pH of the rHSA-containing components of the aged samples at the indicated stability time points (average of three replicate measurements).
[0300]
[0301] The swelling ratio of the hydrogel compositions formed from the four samples shown in Table 1 was evaluated at each stability time point by: (i) 2 The hydrogel composition was formed by hydrating the components of the present invention and the rHSA-containing components, distributing the components by mixing the ends, and forming a gel; (ii) recording the weight of the hydrogel composition at zero time, (iii) incubating the hydrogel composition in a phosphate buffered saline (PBS) solution at 37° C., (iv) removing the hydrogel composition from the PBS solution after two hours; and (v) recording the weight of the hydrogel composition. The swelling percentage was calculated by the percentage increase in weight. The results are shown in Table 6.
[0302] Table 6: Swelling ratio of the tested hydrogel compositions at two hours for aged samples at the indicated stability time points (average of three replicate measurements).
[0303] Time Swelling rate of sample 1 Swelling rate of sample 2 Swelling rate of sample 3 Swelling rate of sample 4 Zero Hour 54.49% 44.63% 39.19% 45.08% 113 days No gel formed 45.77% 65.68% 66.75% 225 days Not tested 30.31% 78.77% 45.90% 338 days Not tested 30.01% Not tested 40.02%
[0304] Example 3
[0305] The following examples describe the liquid bursting pressure strength of hydrogel compositions according to certain embodiments.
[0306] According to Table 7, PEG(SS) was generated. 2 and rHSA. The rHSA-containing component comprises L61 and antioxidants together with lyophilized rHSA. 45 samples of three different hydrogel-forming compositions were studied. The mass percentage by volume of rHSA varied from 10% to 30% between the compositions, and PEG(SS) 2 The amount of was also varied so that the NHS ester:amine ratio remained constant at 2.21 for all three compositions.
[0307] Table 7: Components of the hydrogel-forming compositions tested.
[0308]
[0309] The powder contains PEG(SS) 2 The components of 100% HCl and rHSA were equally divided into their respective syringes and each was hydrated with a separate syringe containing 1 mL of water. The components were then distributed and gelled by mixing the ends. The adhesion of the hydrogel composition was determined by the liquid rupture pressure model based on ASTM F2392-04 (Standard Test Method for Surgical Sealants). The results are shown in Table 8.
[0310] Table 8: Average liquid bursting pressure strength of the hydrogel compositions tested (average of forty-five replicate measurements).
[0311] Composition Average liquid bursting pressure strength (mm Hg) 1 25.92 2 111.83 3 208.97
[0312] Example 4
[0313] The following example describes the evaluation of the hydrogel composition of the present invention applied as a sealant to prevent pneumothorax complications during a lung biopsy procedure in a porcine model.
[0314] Five hydrogel compositions were generated. Treatment of PEG(SS) under nitrogen 2 PEG(SS) 2 The solution of the rHSA-containing component for preparing the rHSA-containing component for forming a hydrogel by lyophilization comprises rHSA to which sodium carbonate, PEG 8000 and L61 and combined it with RO water. The rHSA-containing fraction solution in RO water was lyophilized, ground into powder, aliquoted into a second syringe, and sealed in foil bags under nitrogen.
[0315] Use DI water in the first compartment of the double-barrel syringe (for hydrating the PEG(SS) 2 The hydration kit (e.g., double-barrel syringe) is produced by combining a hydration kit (e.g., double-barrel syringe) with DI water in the second compartment of the double-barrel syringe (for hydrating the lyophilized rHSA-containing component). The hydration kit is sealed in a foil bag with the PEG(SS)-containing 2 Connection to separate syringes of the rHSA-containing components allows the powder mixture to be hydrated with its respective solution at the time of use.
[0316] A total of ten pig subjects were evaluated. Five of the ten pigs were designated as test subjects and implanted with the hydrogel composition in the left lower lobe of the lung. To deliver the hydrogel composition, a coaxial technique was used under the guidance of computed tomography (CT). The delivery device was inserted through the soft tissue until it was adjacent to the lung and pleural cavity (see Fig. 8A The hydrogel composition is hydrated and deployed through a ported needle system of a delivery device into the subcutaneous tissue, pleural cavity, and immediate area of the lung parenchyma (see Figure 8B ). CT imaging was used to determine the placement of the hydrogel.
[0317] After successful implantation of the hydrogel composition, a lung biopsy was performed within five minutes of implantation of the hydrogel composition by using the coaxial cannula. Briefly, the needle was adjusted as needed and pushed to the biopsy site and the port needle delivery system was removed. A standard biopsy needle was inserted through the coaxial system and a standard lung biopsy procedure was continued using CT guidance using a 16G Bard Mission biopsy needle (see Figure 8C ).
[0318] Two of the five subjects were followed up for evaluation at 72 (± 8) hours after hydrogel implantation, and the other three pigs were evaluated 144 (± 8) hours after implantation. During the follow-up evaluation, CT scans were completed to evaluate the presence of the hydrogel composition and the presence (or absence) of pneumothorax. After the CT scans were completed, the animals were euthanized and a full autopsy was performed, in which the target organs (i.e., lungs) were removed for gross pathological observation. The inner chest wall (e.g., parietal pleura) was also examined.
[0319] Five control pigs underwent a lung biopsy procedure as described above, but without the hydrogel composition implanted. Follow-up evaluations (including CT scans to assess the presence (or absence) of pneumothorax) were performed 48 (± 8) hours after the lung biopsy. The animals were then euthanized after their CT scans (unless otherwise indicated) and a full necropsy was performed, in which the target organs were removed for gross pathology observation.
[0320] A summary of the study design is shown in Table 9.
[0321] Table 9: Summary of porcine model study design.
[0322] group Objects# Sealant Lung Location Follow-up period Subjects 1 Left lower lobe 6 days Subjects 2 Left lower lobe 3 days Subjects 3 Left lower lobe 6 days Subjects 4 Left lower lobe 6 days Subjects 5 Left lower lobe 3 days Control subjects 6 Left lower lobe 2 days Control subjects 7 Left lower lobe 2 days Control subjects 8 Left lower lobe 2 days Control subjects 9 Left lower lobe 2 days Control subjects 10 Left lower lobe 2 days
[0323] Prior to the lung biopsy procedure, each of the five subjects was successfully implanted with the hydrogel composition. The deployment of the hydrogel composition was successful and did not cause any immediate problems or concerns to the physician performing the procedure. No pneumothorax complications occurred during the biopsy procedure or during the 20 to 30 minute monitoring period following the procedure. All five subjects survived until their scheduled follow-up date on Day 3 or Day 6. In addition, all five subjects showed no signs of postoperative or delayed pneumothorax following their CT scans (see for Subject 5 (representative) Fig.9A , where arrows indicate the location of the hydrogel). Autopsies showed retained hydrogel material, as expected at day 3 or day 6. The hydrogel compositions in the day 6 subjects (i.e., samples 1, 3, and 4) showed a decrease in hydrogel hardness, indicating resorption. All five subjects showed mild irritation at the parietal pleura around the needle insertion site, but it was not a major concern.
[0324] Five control subjects underwent lung biopsy without application of the hydrogel composition.Two of the five control subjects (ie, subjects 9 and 10) developed intraprocedural pneumothorax and subsequent air embolism as shown by CT. Fig. 9B An example of an air embolism (circled) in subject 9 is shown, and Fig. 9C An example of a pneumothorax (circled) is shown for subject 10. Due to the severity of these complications, these two subjects were terminated after the biopsies were completed. The remaining three control subjects tolerated the lung biopsies, and a follow-up CT scan revealed a large pneumothorax in one pig (i.e., subject 6, see Fig.9D , where a circle indicates a pneumothorax). The other two pigs (i.e., subjects 7 and 8) were clear and had no complications. Necropsy revealed nothing noteworthy in any of the control subjects.
[0325] A summary of the test results is shown in Table 10. The results showed that the outcome of the lung biopsy procedure was improved in the test subjects (pneumothorax rate 0%) compared to the control subjects (pneumothorax rate 60%).
[0326] Table 10: Summary of test results evaluating pneumothorax in test and control subjects.
[0327] Objects# Post-biopsy pneumothorax Follow-up pneumothorax Autopsy Notes 1 Negative Negative Mild irritation of the parietal pleura 2 Negative Negative Mild irritation of the parietal pleura 3 Negative Negative Very mild irritation of the parietal pleura 4 Negative Negative Mild irritation of the parietal pleura 5 Negative Negative Irritation of the parietal pleura 6 Negative Positive Nothing worth noting 7 Negative Negative Nothing worth noting 8 Negative Negative Nothing worth noting 9 Positive N / A Nothing worth noting 10 Positive N / A Nothing worth noting
[0328] Although several embodiments of the present invention have been described and illustrated herein, a person of ordinary skill in the art will readily conceive of a variety of other means and / or structures for performing the functions described herein and / or obtaining the results and / or one or more advantages described herein, and each of such changes and / or modifications is considered to be within the scope of the present invention. More generally, it will be readily understood by those skilled in the art that all parameters, dimensions, materials, and configurations described herein are intended to be exemplary, and that the actual parameters, dimensions, materials, and / or configurations will depend on the specific application or applications in which the teachings of the present invention are used. Those skilled in the art will recognize or be able to determine many equivalents of the specific embodiments of the present invention described herein using only routine experiments. Therefore, it should be understood that the foregoing embodiments are presented only as examples, and within the scope of the appended claims and their equivalents, the present invention may be implemented in other ways except for the specific description and protection claimed. The present invention relates to each individual feature, system, product, material, and / or method described herein. In addition, if such features, systems, products, materials, and / or methods are not mutually inconsistent, any combination of two or more such features, systems, products, materials, and / or methods is included within the scope of the present invention.
[0329] Unless explicitly stated to the contrary, as used herein in the specification and claims, nouns without quantifiers should be understood to mean "at least one".
[0330] The phrase "and / or" as used herein in the specification and claims should be understood to mean "either or both" of the elements so combined, i.e., elements that exist together in some cases and separately in other cases. Unless expressly indicated to the contrary, other elements other than those specifically identified by the "and / or" clause may optionally be present, whether related or unrelated to those specifically indicated. Thus, as a non-limiting example, when used in conjunction with open-ended language such as "comprising / including", a reference to "A and / or B" may refer to A without B (optionally including elements other than B) in one embodiment; to B without A (optionally including elements other than A) in another embodiment; to both A and B (optionally including other elements) in yet another embodiment; and so on. As used herein in the specification and claims, "or / or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or / or" or "and / or" should be interpreted as inclusive, i.e., including at least one of a plurality of elements or a list of elements, but also including more than one, and optionally additional unlisted items. Only explicit indication of the opposite term, such as "only one of" or "exactly one of", or when used in a claim, "consisting of..." will refer to including exactly one element of a plurality of elements or a list of elements. In general, the term "or / or" as used herein should only be interpreted as indicating exclusive alternatives (i.e., "one or the other but not both") when preceded by an exclusive term (e.g., "either", "one of", "only one of", or "exactly one of"). "Substantially consisting of..." when used in a claim should have its ordinary meaning as used in the field of patent law.
[0331] As used herein in the specification and in the claims, the phrase "at least one" when referring to a list of one or more elements should be understood to mean at least one element selected from any one or more elements in the list of elements, but does not necessarily include at least one of each and every element specifically listed in the list of elements, and does not exclude any combination of elements in the list of elements. This definition also allows that elements other than the elements specifically indicated in the list of elements referred to by the phrase "at least one" may optionally be present, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, "at least one of A and B" (or equivalently, "at least one of A or B", or equivalently "at least one of A and / or B") may refer to at least one A, optionally including more than one A, without the presence of B (and optionally including elements other than B) in one embodiment; to at least one B, optionally including more than one B, without the presence of A (and optionally including elements other than A) in another embodiment; to at least one A, optionally including more than one A, and at least one B, optionally including more than one B (and optionally including other elements) in yet another embodiment; and so on.
[0332] In the claims and the above specification, all transitional phrases such as "comprising," "including," "with," "having," "containing," "involving," "having," etc. shall be understood as open-ended, i.e., meaning including but not limited to. As described in Section 2111.03 of the United States Patent Office Manual of Patent Examining Procedures, only the transitional phrases "consisting of" and "consisting essentially of" shall be closed or semi-closed transitional phrases, respectively.
[0333] The present invention also relates to the following embodiments (which correspond to the claims of the original application):
[0334] 1. A hydrogel-forming composition for forming a hydrogel tissue sealant, comprising:
[0335] The first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0336] G-LM-PEG-LM-G;
[0337] in:
[0338] PEG is polyethylene glycol;
[0339] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0340] each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; and
[0341] a second component comprising a protein capable of being cross-linked with the cross-linking agent;
[0342] one or more solvents capable of dissolving the first component and the second component;
[0343] and surfactants;
[0344] When the first component, the second component and the surfactant are all dissolved in the one or more solvents, the cross-linking agent cross-links with the protein to form the hydrogel tissue sealant.
[0345] 2. A hydrogel-forming composition for forming a hydrogel tissue sealant, comprising:
[0346] A crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0347] G-LM-PEG-LM-G;
[0348] in:
[0349] PEG is polyethylene glycol;
[0350] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d- represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0351] each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl;
[0352] a protein capable of being cross-linked with the cross-linking agent;
[0353] one or more solvents capable of dissolving the first component and the second component;
[0354] and surfactants;
[0355] When the cross-linking agent, the protein and the surfactant are all dissolved in the one or more solvents, the cross-linking agent cross-links with the protein to form the hydrogel tissue sealant.
[0356] 3. A hydrogel-forming composition for forming a hydrogel tissue sealant, comprising:
[0357] The first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0358] G-LM-PEG-LM-G;
[0359] in:
[0360] PEG is polyethylene glycol;
[0361] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 )c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0362] each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; and
[0363] a second component comprising a protein capable of being cross-linked with the cross-linking agent; and
[0364] one or more solvents capable of dissolving the first component and the second component;
[0365] Wherein when the first component and the second component are dissolved in the one or more solvents, after the first component dissolved in the one or more solvents is mixed with the second component, the cross-linking agent and the protein are cross-linked with a gel time of less than or equal to 20 seconds to form the hydrogel tissue sealant.
[0366] 4. A hydrogel-forming composition for forming a hydrogel tissue sealant, comprising:
[0367] The first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0368] G-LM-PEG-LM-G;
[0369] in:
[0370] PEG is polyethylene glycol;
[0371] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0372] each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; and
[0373] a second component comprising a protein capable of being cross-linked with the cross-linking agent; and
[0374] a first solvent and a second solvent, wherein the first solvent is capable of dissolving the first component and the second solvent is capable of dissolving the second component;
[0375] wherein when the second component is dissolved in the second solvent, the pH of the solution of the second component in the second solvent is greater than or equal to 10.2 and less than or equal to 10.6; and wherein when the first component is dissolved in the first solvent and combined with the solution of the second component in the second solvent, a cross-linked solution of the first component and the second component is formed.
[0376] 5. A hydrogel-forming composition for forming a hydrogel tissue sealant, comprising:
[0377] The first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0378] G-LM-PEG-LM-G;
[0379] in:
[0380] PEG is polyethylene glycol;
[0381] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -.R-(CH 2 ) c-C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0382] each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; and
[0383] a second component comprising a protein capable of being cross-linked with the cross-linking agent; and
[0384] One or more solvents capable of dissolving the first component and the second component such that when the first component and the second component are individually mixed with the one or more solvents, at least the second component can have a dissolution time of less than or equal to 30 seconds at 25°C.
[0385] 6. The composition of any one of embodiments 3 to 5, further comprising a surfactant.
[0386] 7. The composition of any one of embodiments 1, 2 or 6, wherein the surfactant is capable of stabilizing the protein, increasing the rate at which the protein dissolves, and / or preventing aggregation of the protein.
[0387] 8. The composition of any one of embodiments 1 to 7, further comprising a cross-linking initiator.
[0388] 9. The composition of embodiment 8, wherein the cross-linking initiator is part of the second component.
[0389] 10. The composition of any one of embodiments 1 to 9, wherein the surfactant is part of the second component.
[0390] 11. The composition of embodiment 10, wherein the second component is a lyophilized powder comprising both the protein and the surfactant before being dissolved in the one or more solvents.
[0391] 12. The composition of any one of embodiments 1 to 11, wherein at least one of the one or more solvents is water or an aqueous solution.
[0392] 13. The composition of any one of embodiments 1 to 11, wherein at least one of the one or more solvents is an organic solvent.
[0393] 14. The composition of embodiment 13, wherein the organic solvent comprises dimethyl sulfoxide (DMSO).
[0394] 15. The composition of any one of embodiments 1 to 14, further comprising a first antioxidant.
[0395] 16. The composition of embodiment 15, wherein the first antioxidant is part of the first component.
[0396] 17. The composition of any one of embodiments 1 to 16, wherein:
[0397] Each LM is identical and is a bifunctional linking moiety represented by the formula: -C(O)-; -(CH 2 ) b -C(O)-, wherein b is an integer from 1 to 5; -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 2 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; -C(O)-O-(CH 2 ) d -OC(O)-, wherein d is an integer from 2 to 10; and -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-or-RC(O)-O-(CH 2 ) d -OC(O)- represented by an oligomeric diradical, wherein c is an integer from 2 to 10, d is an integer from 2 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0398] Each G is the same and is a leaving group selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl and trifluoroethanesulfonyl.
[0399] 18. The composition of any one of embodiments 1 to 17, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0400]
[0401] Polyethylene glycol disuccinimidyl succinate.
[0402] 19. The composition of any one of embodiments 1 to 17, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0403]
[0404] 20. The composition of any one of embodiments 1 to 19, wherein the protein is selected from human serum albumin, recombinant human serum albumin, and animal-derived albumin.
[0405] 21. The composition of any one of embodiments 1 to 20, wherein the protein is recombinant human serum albumin.
[0406] 22. The composition of any one of embodiments 1 to 21, wherein the protein is lyophilized.
[0407] 23. The composition of any one of embodiments 8 to 22, wherein the cross-linking initiator comprises a base and / or a basic buffer.
[0408] 24. The composition of embodiment 23, wherein the base and / or alkaline buffer comprises carbonate and / or bicarbonate.
[0409] 25. The composition of embodiment 23, wherein the base and / or alkaline buffer comprises sodium carbonate.
[0410] 26. The composition of embodiment 23, wherein the base and / or alkaline buffer comprises sodium bicarbonate.
[0411] 27. The composition of any one of embodiments 15 to 26, wherein the first antioxidant is butylated hydroxytoluene.
[0412] 28. The composition of any one of embodiments 1, 2, or 7 to 27, wherein the surfactant is a non-functionalized PEG.
[0413] 29. The composition of embodiment 28, wherein the weight average molecular weight of the non-functionalized PEG is greater than or equal to 1000 g / mol and less than or equal to 40000 g / mol.
[0414] 30. The composition of embodiment 29, wherein the weight average molecular weight of the non-functionalized PEG is 8000 g / mol.
[0415] 31. The composition of any one of embodiments 1, 2, or 7 to 27, wherein the surfactant is dextran sulfate.
[0416] 32. The composition of any one of embodiments 1, 2, or 7 to 27, wherein the surfactant is a poloxamer, a polysorbate, an oil, a silicone, a stearate, and a glycol.
[0417] 33. The composition of embodiment 32, wherein the poloxamer is L61.
[0418] 34. The composition of embodiment 32, wherein the oil is a mineral oil or a vegetable oil.
[0419] 35. The composition of embodiment 33, wherein the surfactant is a defoaming additive.
[0420] 36. The composition of any one of embodiments 15 to 35, further comprising a second antioxidant.
[0421] 37. The composition of embodiment 36, wherein the second antioxidant is N-acetyl-DL-tryptophan.
[0422] 38. The composition of any one of embodiments 1 or 3 to 37, wherein the first component is in the form of a first powder or powder mixture.
[0423] 39. The composition of embodiment 2, wherein the cross-linking agent is in the form of a first powder or powder mixture.
[0424] 40. The composition of any one of embodiments 1 or 3 to 38, wherein the second component is in the form of a second powder or powder mixture.
[0425] 41. The composition of embodiment 2 or 39, wherein the protein is in the form of a second powder or powder mixture.
[0426] 42. The composition of any one of embodiments 1 or 3 to 37, wherein the first component is in the form of a first aqueous solution.
[0427] 43. The composition of embodiment 2, wherein the cross-linking agent is in the form of a first aqueous solution.
[0428] 44. The composition of any one of embodiments 1 or 3 to 37, wherein the second component is in the form of a second aqueous solution.
[0429] 45. The composition of embodiment 2 or 43, wherein the protein is in the form of a second aqueous solution.
[0430] 46. The composition of any one of embodiments 1 to 37, wherein the composition comprises one or more powders or powder mixtures.
[0431] 47. The composition of any one of embodiments 1 to 37, wherein the composition comprises one or more aqueous solutions.
[0432] 48. The composition of embodiment 42, wherein the first aqueous solution comprises a radiopaque agent.
[0433] 49. The composition of any one of embodiments 1 to 37, wherein the composition comprises a radiopaque agent.
[0434] 50. The composition of embodiment 48 or 49, wherein the radiopaque agent comprises gold, silver, or iodine.
[0435] 51. The composition of embodiment 48 or 49, wherein the radiopaque agent is KCl, barium sulfate, iohexol, or diatrizoate.
[0436] 52. The composition of any one of embodiments 1 or 3 to 51, wherein when the first component, the second component and the surfactant are all dissolved in the one or more solvents, the measured gel time of the resulting hydrogel-forming composition is greater than or equal to 0.1 seconds and less than or equal to 5 seconds.
[0437] 53. The composition of embodiment 2, wherein, when the cross-linking agent, the protein and the surfactant are all dissolved in the one or more solvents, the measured gel time of the resulting hydrogel-forming composition is greater than or equal to 0.1 seconds and less than or equal to 5 seconds.
[0438] 54. The composition of any one of embodiments 1 or 3 to 52, wherein, when the first component, the second component, and the surfactant are all dissolved in the one or more solvents, the measured pot life of the resulting hydrogel-forming composition is greater than or equal to 10 minutes and less than or equal to 24 hours.
[0439] 55. The composition of embodiment 2 or 53, wherein, when the cross-linking agent, the protein, and the surfactant are all dissolved in the one or more solvents, the measured pot life of the resulting hydrogel-forming composition is greater than or equal to 10 minutes and less than or equal to 24 hours.
[0440] 56. A method of forming a hydrogel tissue sealant, comprising:
[0441] A first component is dissolved in a first solvent, wherein the first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0442] G-LM-PEG-LM-G;
[0443] in:
[0444] PEG is polyethylene glycol;
[0445] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 )b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0446] each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl;
[0447] dissolving a second component in a second solvent, wherein the second component comprises a protein capable of being cross-linked with the cross-linking agent, and
[0448] The dissolved first component is combined with the dissolved second component to form a hydrogel-forming composition comprising the cross-linking agent, the protein, and a surfactant to induce cross-linking of the cross-linking agent with the protein to form the hydrogel tissue sealant.
[0449] 57. A method of forming a hydrogel tissue sealant, comprising:
[0450] A first component is dissolved in a first solvent, wherein the first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0451] G-LM-PEG-LM-G;
[0452] in:
[0453] PEG is polyethylene glycol;
[0454] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0455] each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl;
[0456] dissolving a second component in a second solvent, wherein the second component comprises a protein capable of being cross-linked with the cross-linking agent, and
[0457] The dissolved first component is combined with the dissolved second component to form a hydrogel-forming composition comprising the cross-linking agent and the protein, thereby inducing cross-linking of the cross-linking agent with the protein to form the hydrogel tissue sealant such that the cross-linking is characterized by a gel time of less than or equal to 20 seconds.
[0458] 58. A method of forming a hydrogel tissue sealant comprising:
[0459] A first component is dissolved in a first solvent to form a solution of the first component, wherein the first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0460] G-LM-PEG-LM-G;
[0461] in:
[0462] PEG is polyethylene glycol;
[0463] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 )c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0464] each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl;
[0465] dissolving a second component in a second solvent to form a solution of the second component, wherein the second component comprises a protein capable of being cross-linked with the cross-linking agent, and wherein the pH of the solution of the second component is greater than or equal to 10.2 and less than or equal to 10.6, and
[0466] The solution of the first component is combined with the solution of the second component to form a hydrogel-forming composition comprising the cross-linking agent and the protein, thereby inducing cross-linking of the cross-linking agent with the protein to form the hydrogel tissue sealant.
[0467] 59. A method of forming a hydrogel tissue sealant comprising:
[0468] A first component is dissolved in a first solvent, wherein the first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0469] G-LM-PEG-LM-G;
[0470] in:
[0471] PEG is polyethylene glycol;
[0472] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c-C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0473] each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl;
[0474] dissolving a second component in a second solvent, wherein the second component comprises a protein capable of being cross-linked with the cross-linking agent, wherein the dissolution time of the second component in the second solvent at 25° C. is less than or equal to 30 seconds; and
[0475] The dissolved first component is combined with the dissolved second component to form a hydrogel-forming composition comprising the cross-linking agent and the protein, thereby initiating cross-linking of the cross-linking agent with the protein to form the hydrogel tissue sealant.
[0476] 60. The method of any one of embodiments 57 to 59, wherein the hydrogel-forming composition further comprises a surfactant.
[0477] 61. The method of embodiment 56 or 60, wherein the surfactant is capable of stabilizing the protein, increasing the rate at which the protein dissolves in the second solvent, and / or preventing aggregation of the protein.
[0478] 62. The method of any one of embodiments 56 to 61, wherein the first component is a second powdered component.
[0479] 63. The method of any one of embodiments 56 to 62, wherein the second component is a second powdered component.
[0480] 64. The method of any one of embodiments 56 to 63, wherein the first solvent comprises water, an organic solvent, or a first aqueous solution.
[0481] 65. The method of any one of embodiments 56 to 64, wherein the second solvent comprises water, an organic solvent, or a second aqueous solution.
[0482] 66. A method of forming a hydrogel tissue sealant comprising:
[0483] forming a hydrogel-forming composition comprising:
[0484] A crosslinking agent which is a difunctional polyalkylene oxide based component of the formula:
[0485] G-LM-PEG-LM-G;
[0486] in:
[0487] PEG is polyethylene glycol;
[0488] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0489] each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl;
[0490] a protein capable of being cross-linked with the cross-linking agent; and
[0491] Surfactants;
[0492] The hydrogel-forming composition, after being formed, causes the cross-linking agent to initiate cross-linking with the protein, thereby forming the hydrogel tissue sealant.
[0493] 67. The method of embodiment 66, wherein the surfactant is capable of stabilizing the protein, increasing the rate at which the protein dissolves in the solution, and / or preventing the protein from aggregating.
[0494] 68. The method of embodiment 66 or 67, wherein the hydrogel-forming composition comprises water, an organic solvent, or a first aqueous solution.
[0495] 69. A method of sealing tissue, comprising:
[0496] delivering a hydrogel-forming composition to a tissue site, wherein the hydrogel-forming composition comprises the reaction product of:
[0497] The first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0498] G-LM-PEG-LM-G;
[0499] in:
[0500] PEG is polyethylene glycol;
[0501] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0502] each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; and
[0503] a second component comprising a protein capable of being cross-linked with the cross-linking agent; and
[0504] The hydrogel-forming composition further comprises a surfactant.
[0505] 70. A method of sealing tissue, comprising:
[0506] delivering a hydrogel-forming composition to a tissue site, wherein the hydrogel-forming composition is the reaction product of:
[0507] A solution of a first component comprising a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0508] G-LM-PEG-LM-G;
[0509] in:
[0510] PEG is polyethylene glycol;
[0511] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-,
[0512] -RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0513] each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; and
[0514] A solution of a second component, the second component comprising a protein capable of being cross-linked with the cross-linking agent, wherein the pH of the solution of the second component is greater than or equal to 10.2 and less than or equal to 10.6.
[0515] 71. A method of sealing tissue, comprising:
[0516] A hydrogel-forming composition is delivered to a tissue site, wherein the hydrogel composition comprises the reaction product of:
[0517] The first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0518] G-LM-PEG-LM-G;
[0519] in:
[0520] PEG is polyethylene glycol;
[0521] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 )bC(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d- an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0522] each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; and
[0523] a second component comprising a protein capable of being cross-linked with the cross-linking agent; and
[0524] A hydrogel tissue sealant is formed at the tissue site via a cross-linking reaction characterized by a gel time of less than or equal to 20 seconds.
[0525] 72. The method of embodiment 69, wherein the surfactant is capable of stabilizing the protein, increasing the rate at which the protein dissolves in the solvent, and / or preventing the protein from aggregating prior to dissolving in the solvent.
[0526] 73. The method of any one of embodiments 69 to 72, wherein the cross-linked hydrogel tissue sealant is formed before and / or after delivery to the tissue site.
[0527] 74. The method of any one of embodiments 69 to 73, wherein the first component is a first aqueous solution.
[0528] 75. The method of any one of embodiments 69 to 74, wherein the second component is a second aqueous solution.
[0529] 76. The method of any one of embodiments 69 to 75, wherein the hydrogel-forming composition further comprises a cross-linking initiator.
[0530] 77. The method of embodiment 76, wherein the cross-linking initiator is part of the second component.
[0531] 78. The method of any one of embodiments 56 to 65 and 69 to 77, wherein the surfactant is part of the second component.
[0532] 79. The method of embodiment 78, wherein the second component is a lyophilized powder comprising both the protein and the surfactant prior to dissolution.
[0533] 80. The method of any one of embodiments 56 to 79, wherein the hydrogel-forming composition further comprises at least one antioxidant.
[0534] 81. The method of any one of embodiments 56 to 65 and 69 to 80, wherein the at least one antioxidant is part of the first component.
[0535] 82. The method of any one of embodiments 56 to 81, wherein:
[0536] Each LM is identical and is a bifunctional linking moiety represented by the formula: -C(O)-; -(CH 2 ) b -C(O)-, wherein b is an integer from 1 to 5; -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 2 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; -C(O)-O-(CH 2 ) d -OC(O)-, wherein d is an integer from 2 to 10; and -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-or-RC(O)-O-(CH 2 ) d -OC(O)- represented by an oligomeric diradical, wherein c is an integer from 2 to 10, d is an integer from 2 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0537] Each G is the same and is a leaving group selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl and trifluoroethanesulfonyl.
[0538] 83. The method of any one of embodiments 56 to 82, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0539]
[0540] Polyethylene glycol disuccinimidyl succinate.
[0541] 84. The method of any one of embodiments 56 to 82, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0542]
[0543] 85. The method of any one of embodiments 56 to 84, wherein the protein is selected from human serum albumin, recombinant human serum albumin, and animal-derived albumin.
[0544] 86. The method of any one of embodiments 56 to 85, wherein the protein is recombinant human serum albumin.
[0545] 87. The method of any one of embodiments 56 to 86, wherein the protein is lyophilized.
[0546] 88. The method of any one of embodiments 76 to 87, wherein the cross-linking initiator comprises a base and / or a basic buffer.
[0547] 89. The method of embodiment 88, wherein the base and / or alkaline buffer comprises carbonate and / or bicarbonate.
[0548] 90. The method of embodiment 89, wherein the base and / or alkaline buffer comprises sodium carbonate.
[0549] 91. The method of embodiment 89, wherein the base and / or alkaline buffer comprises sodium bicarbonate.
[0550] 92. The method of any one of embodiments 80 to 91, wherein the at least one antioxidant is butylated hydroxytoluene.
[0551] 93. The method of any one of embodiments 56 to 92, wherein the surfactant is a non-functionalized PEG.
[0552] 94. The method of embodiment 93, wherein the weight average molecular weight of the non-functionalized PEG is greater than or equal to 1000 g / mol and less than or equal to 40000 g / mol.
[0553] 95. The method of embodiment 94, wherein the weight average molecular weight of the non-functionalized PEG is 8000 g / mol.
[0554] 96. The method of any one of embodiments 56 to 95, wherein the surfactant is dextran sulfate.
[0555] 97. The method of any one of embodiments 56 to 92, wherein the surfactant is a poloxamer, a polysorbate, an oil, a silicone, a stearate, and a glycol.
[0556] 98. The method of embodiment 97, wherein the poloxamer is Pluronic L61.
[0557] 99. The method of embodiment 97, wherein the oil is mineral oil or vegetable oil.
[0558] 100. The method of embodiment 98, wherein the surfactant is a defoaming additive.
[0559] 101. The method of any one of embodiments 56 to 100, wherein the hydrogel tissue sealant further comprises a second antioxidant.
[0560] 102. The method of embodiment 101, wherein the second antioxidant is N-acetyl-DL-tryptophan.
[0561] 103. The method of any one of embodiments 56 to 102, wherein the hydrogel-forming composition further comprises a radiopaque agent.
[0562] 104. The method of embodiment 103, wherein the radiopaque agent comprises gold, silver, or iodine.
[0563] 105. The method of embodiment 103, wherein the radiopaque agent is KCl, barium sulfate, iohexol, or diatrizoate.
[0564] 106. A kit for forming a hydrogel tissue sealant, comprising:
[0565] A first component contained in a first container, wherein the first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0566] G-LM-PEG-LM-G;
[0567] in:
[0568] PEG is polyethylene glycol;
[0569] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b-C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0570] each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; and
[0571] A second component is contained in a second container, wherein the second component comprises a protein capable of being cross-linked with the cross-linking agent, and a surfactant.
[0572] 107. A kit for forming a hydrogel tissue sealant, comprising:
[0573] A first component in powder form contained in a first container, wherein the first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0574] G-LM-PEG-LM-G;
[0575] in:
[0576] PEG is polyethylene glycol;
[0577] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 )dC(O)-, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0578] each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl;
[0579] a second component in powder form contained in a second container, wherein the second component comprises a protein capable of cross-linking with the cross-linking agent;
[0580] a first aqueous hydrating solution contained in a third container, wherein the first aqueous hydrating solution is capable of dissolving the first component; and
[0581] A second aqueous hydrating solution is contained within a fourth container, wherein the second aqueous hydrating solution is capable of dissolving the second component.
[0582] 108. The kit of embodiment 107, further comprising a surfactant.
[0583] 109. The kit of embodiment 106 or 108, wherein the surfactant is capable of stabilizing the protein, increasing the rate at which the protein dissolves in a solvent, and / or preventing aggregation of the protein.
[0584] 110. The kit of any one of embodiments 106 to 109, further comprising a cross-linking initiator.
[0585] 111. The kit of embodiment 110, wherein the cross-linking initiator is part of the second component.
[0586] 112. The kit of any one of embodiments 108 to 111, wherein the surfactant is part of the second component.
[0587] 113. The kit of embodiment 112, wherein the second component is a lyophilized powder comprising both the protein and the surfactant.
[0588] 114. The kit of any one of embodiments 106 to 113, further comprising a first antioxidant.
[0589] 115. The kit of embodiment 114, wherein the first antioxidant is part of the first component.
[0590] 116. The kit of embodiment 106, wherein the kit further comprises: a third component contained in a third container, wherein the third component comprises the first solvent or solution.
[0591] 117. The kit of embodiment 106 or 116, wherein the kit further comprises: a fourth component contained in a fourth container, wherein the fourth component comprises a second solvent or solution.
[0592] 118. The kit of embodiment 117, wherein one or more of the first container, the second container, the third container, and the fourth container is a compartment of a syringe or an applicator.
[0593] 119. The kit of any one of embodiments 106 to 118, wherein:
[0594] Each LM is identical and is a bifunctional linking moiety represented by the formula: -C(O)-; -(CH 2 ) b -C(O)-, wherein b is an integer from 1 to 5; -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 2 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; -C(O)-O-(CH 2 ) d -OC(O)-, wherein d is an integer from 2 to 10; and -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-or-RC(O)-O-(CH 2 ) d -OC(O)- represented by an oligomeric diradical, wherein c is an integer from 2 to 10, d is an integer from 2 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0595] Each G is the same and is a leaving group selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl and trifluoroethanesulfonyl.
[0596] 120. The kit of any one of embodiments 106 to 119, wherein the cross-linking agent is a difunctional polyalkylene oxide-based component of the formula:
[0597]
[0598] Polyethylene glycol disuccinimidyl succinate.
[0599] 121. The kit of any one of embodiments 106 to 119, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0600]
[0601] 122. The kit of any one of embodiments 106 to 121, wherein the protein is selected from human serum albumin, recombinant human serum albumin, and animal-derived albumin.
[0602] 123. The kit of any one of embodiments 106 to 122, wherein the protein is recombinant human serum albumin.
[0603] 124. The kit of any one of embodiments 106 to 123, wherein the protein is lyophilized.
[0604] 125. The kit of any one of embodiments 110 to 124, wherein the cross-linking initiator comprises a base and / or a basic buffer.
[0605] 126. The kit of embodiment 125, wherein the base and / or alkaline buffer comprises carbonate and / or bicarbonate.
[0606] 127. The kit of embodiment 125, wherein the base and / or alkaline buffer comprises sodium carbonate.
[0607] 128. The kit of embodiment 125, wherein the base and / or alkaline buffer comprises sodium bicarbonate.
[0608] 129. The kit of any one of embodiments 114 to 128, wherein the first antioxidant is butylated hydroxytoluene.
[0609] 130. The kit of any one of embodiments 106 or 108 to 129, wherein the surfactant is a non-functionalized PEG.
[0610] 131. The kit of embodiment 130, wherein the weight average molecular weight of the non-functionalized PEG is greater than or equal to 1000 g / mol and less than or equal to 40000 g / mol.
[0611] 132. The kit of embodiment 130, wherein the weight average molecular weight of the non-functionalized PEG is 8000 g / mol.
[0612] 133. The kit of any one of embodiments 106 or 108 to 129, wherein the surfactant is dextran sulfate.
[0613] 134. The kit of any one of embodiments 106 or 108 to 129, wherein the surfactant is a poloxamer, a polysorbate, an oil, a silicone, a stearate, and a glycol.
[0614] 135. The kit of embodiment 134, wherein the poloxamer is L61.
[0615] 136. The kit of embodiment 134, wherein the oil is mineral oil or vegetable oil.
[0616] 137. The kit of embodiment 135, wherein the surfactant is a defoaming additive.
[0617] 138. The kit of any one of embodiments 114 to 137, further comprising a second antioxidant.
[0618] 139. The kit of embodiment 138, wherein the second antioxidant is N-acetyl-DL-tryptophan.
[0619] 140. The kit of any one of embodiments 106 to 139, further comprising a radiopaque agent.
[0620] 141. The kit of embodiment 140, wherein the radiopaque agent comprises gold, silver, or iodine.
[0621] 142. The kit of embodiment 140, wherein the radiopaque agent is KCl, barium sulfate, iohexol, or diatrizoate.
[0622] 143. A kit for forming a hydrogel tissue sealant, comprising:
[0623] one or more syringes collectively comprising at least three separate containers, wherein a first container comprises a first component in powder form, a second container comprises a second component in powder form, and at least a third container comprises one or more solvents, wherein the one or more syringes are configured such that the first container and the second container can be placed in fluid communication with the at least third container comprising the one or more solvents to facilitate mixing of the first component with the one or more solvents to form a solution of the first component and to facilitate mixing of the second component with the one or more solvents to form a solution of the second component, and wherein the one or more syringes are further configured to mix the solution of the first component with the solution of the second component to form a cross-linked solution of the first component and the second component that is capable of forming the hydrogel tissue sealant;
[0624] The first component comprises an electrophilic biodegradable polymer, and the second component comprises a nucleophilic biodegradable polymer capable of cross-linking with the electrophilic biodegradable polymer.
[0625] 144. The kit of embodiment 143, wherein the kit comprises:
[0626] Two syringes,
[0627] wherein the first syringe comprises the first container containing the first component in powder form, and further comprises the second container containing the second component in powder form,
[0628] wherein the second syringe comprises a third container containing a first solvent capable of dissolving the first component, and a fourth container containing a second solvent capable of dissolving the second component;
[0629] wherein the first syringe and the second syringe are configured to be fluidly connectable to each other, so that the first container and the second container can be placed in fluid communication with the third container and the fourth container, respectively, to promote mixing of the first component with the first solvent capable of dissolving the first component to form a solution of the first component in the first container, and to promote mixing of the second component with the second solvent capable of dissolving the second component to form a solution of the second component in the second container; and
[0630] The first syringe is further configured to mix a solution of the first component with a solution of the second component to form a cross-linked mixture of the first component and the second component, which is capable of forming the hydrogel tissue sealant.
[0631] 145. The kit of embodiment 144, wherein the first component comprises a cross-linking agent, wherein the cross-linking agent is a difunctional polyalkylene oxide-based component of the formula:
[0632] G-LM-PEG-LM-G;
[0633] in:
[0634] PEG is polyethylene glycol;
[0635] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d- an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c -C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0636] Each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl.
[0637] 146. The kit of embodiment 144 or 145, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula:
[0638]
[0639] Polyethylene glycol disuccinimidyl succinate.
[0640] 147. The kit of any one of embodiments 144 to 146, wherein the second component comprises a protein capable of cross-linking with the cross-linking agent.
[0641] 148. The kit of embodiment 147, wherein the protein is albumin.
[0642] 149. The kit of embodiment 148, wherein the albumin is recombinant human serum albumin.
[0643] 150. The kit of any one of embodiments 144 to 149, wherein the second component comprises a cross-linking initiator.
[0644] 151. The kit of any one of embodiments 144 to 150, wherein the second component comprises a surfactant.
[0645] 152. The kit of any one of embodiments 144 to 151, wherein the first solvent comprises water or an aqueous solution.
[0646] 153. The kit of any one of embodiments 144 to 152, wherein the second solvent comprises water or an aqueous solution.
[0647] 154. The kit of any one of embodiments 144 to 151, wherein the second solvent comprises a defoaming agent.
[0648] 155. A hydrogel-forming composition for forming a hydrogel tissue sealant, comprising:
[0649] The first component comprises a crosslinking agent, the crosslinking agent being a difunctional polyalkylene oxide-based component of the formula:
[0650] G-LM-PEG-LM-G;
[0651] in:
[0652] PEG is polyethylene glycol;
[0653] Each LM is a bifunctional linking moiety independently selected from the following: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 ) b -C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula -C(O)-(CH 2 ) c -C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; a diester group of the formula -C(O)-O-(CH 2 ) d -OC(O)- dicarbonate diradical, wherein d is an integer from 1 to 10; a dicarbonate diradical of the formula -N(H)-C(O)-(CH 2 ) d -C(O)- containing amide diradicals, wherein d is an integer from 1 to 10; 2 ) c -C(O)-N(H)-(CH 2 ) d - an amide-containing diradical, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diradical of the formula -RC(O)-, -RC(O)-(CH 2 ) c -C(O)-, -RC(O)-O-(CH 2 ) d -OC(O)-、-RN(H)-C(O)-(CH 2 ) d -C(O)- or -R-(CH 2 ) c-C(O)-N(H)-(CH 2 ) d - represented by an oligomeric diradical, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and
[0654] each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl;
[0655] a second component comprising a protein capable of being cross-linked with the cross-linking agent; and
[0656] one or more solvents;
[0657] The first component and the second component are dissolved in the one or more solvents.
[0658] 156. The hydrogel-forming composition of embodiment 155, wherein the difunctionalized polyalkylene oxide-based component has the formula G-LM-(OCH 2 CH 2 ) n O-LM-G, wherein n is an integer from 10 to 500, preferably an integer from 50 to 200.
[0659] 157. The hydrogel-forming composition of embodiment 155 or 156, wherein the leaving group G in the difunctionalized polyalkylene oxide-based component is an N-oxysuccinimide group.
[0660] 158. The hydrogel-forming composition of any one of embodiments 155 to 157, wherein the bifunctional linking moiety LM in the bifunctionalized polyalkylene oxide-based component is selected from -(CH 2 ) b -C(O)- and -C(O)-(CH 2 ) c -C(O)-, wherein both b and c are integers of 1 to 10.
[0661] 159. The hydrogel-forming composition of any one of embodiments 155 to 158, wherein the difunctionalized polyalkylene oxide-based component is selected from:
[0662]
[0663] In both formulae, n is an integer of 10 to 500, preferably an integer of 50 to 200.
[0664] 160. The hydrogel-forming composition of any one of embodiments 1 to 159, wherein the protein is selected from human serum albumin, recombinant human serum albumin, and animal-derived albumin.
[0665] 161. The hydrogel-forming composition of any one of embodiments 1 to 160, wherein the protein is recombinant human serum albumin.
[0666] 162. The hydrogel-forming composition of any one of embodiments 1 to 161, wherein the composition further comprises a surfactant dissolved in the one or more solvents.
[0667] 163. The hydrogel-forming composition of embodiment 162, wherein the surfactant is selected from non-functionalized PEG, dextran sulfate, poloxamer, polysorbate, oil, silicone, stearate and / or glycol, and the non-functionalized PEG preferably has a weight average molecular weight of 1000 g / mol to 40000 g / mol.
[0668] 164. The hydrogel-forming composition of any one of embodiments 155 to 163, wherein the one or more solvents comprise water, and the amount of water is 50 wt.% to 100 wt.%, preferably 90 wt.% to 100 wt.%, based on the total amount of solvents.
[0669] 165. The hydrogel-forming composition of any one of embodiments 155 to 164, wherein:
[0670] The difunctional polyalkylene oxide-based component is selected from:
[0671]
[0672] wherein in both formulae, n is an integer from 10 to 500, preferably an integer from 50 to 200;
[0673] The protein is recombinant human serum albumin;
[0674] The surfactant is non-functionalized PEG; and
[0675] Water accounts for 90 wt. % or more of the total amount of the one or more solvents.
[0676] 166. The hydrogel-forming composition of any one of embodiments 155 to 165, wherein the composition further comprises a cross-linking initiator, an antioxidant, and / or a radiopaque agent.
[0677] 167. The hydrogel-forming composition of any one of embodiments 155 to 166, wherein the composition comprises a base or alkaline buffer, preferably a carbonate and / or bicarbonate.
[0678] 168. The hydrogel-forming composition of any one of embodiments 155 to 167, wherein the composition comprises an antioxidant, preferably butylated hydroxyanisole, butylated hydroxytoluene, propyl gallate d-alpha tocopheryl polyethylene glycol-1000 succinate or sodium metabisulfite, and / or mixtures thereof.
[0679] 169. The hydrogel-forming composition of any one of embodiments 155 to 168, wherein the composition comprises a radiopaque agent, preferably gold, silver, iodine, potassium chloride, barium sulfate, iohexol or diatrizoate, and / or mixtures thereof.
[0680] 170. The hydrogel-forming composition of any one of embodiments 155 to 169, wherein the first component is dissolved in a first solvent.
[0681] 171. The hydrogel-forming composition of any one of embodiments 155 to 170, wherein the second component is dissolved in a second solvent.
[0682] 172. The hydrogel-forming composition of embodiment 171, wherein the pH of the second component dissolved in the second solvent is 10.2 to 10.6.
[0683] 173. A kit for forming a hydrogel tissue sealant, comprising:
[0684] a first container comprising a first component comprising a cross-linking agent as defined in any one of embodiments 1 to 5;
[0685] a second container comprising a second component comprising a protein, preferably a protein selected from the group consisting of human serum albumin, recombinant human serum albumin and albumin of animal origin; and
[0686] Optionally, one or more additional containers comprising one or more solvents, preferably water, for dissolving the first component and the second component.
[0687] 174. The kit of embodiment 173, wherein the kit comprises:
[0688] a first container comprising the first component;
[0689] a second container comprising the second component; and
[0690] A third container contains a solvent, preferably water, for dissolving the first component and the second component.
[0691] 175. The kit of embodiment 174, wherein the kit comprises:
[0692] Two syringes,
[0693] wherein the first syringe comprises the first container and the second container; and
[0694] wherein the second syringe contains the third container;
[0695] wherein the first component and the second component are in powder form;
[0696] wherein the first syringe and the second syringe are configured to be fluidly connectable to each other so that the first container and the second container can be placed in fluid communication with the third container to facilitate mixing of the first component and the second component with the solvent to form a solution of the first component in the first container and a solution of the second component in the second container, and
[0697] The first syringe is further configured to mix the solution of the first component with the solution of the second component to form a hydrogel-forming composition for forming a hydrogel tissue sealant.
[0698] 176. The kit of embodiment 173, wherein the kit comprises:
[0699] a first container comprising the first component;
[0700] a second container comprising the second component;
[0701] a third container comprising a solvent for dissolving the first component, preferably water; and
[0702] A fourth container comprises a solvent for dissolving the second component, preferably water.
[0703] 177. The kit of embodiment 176, wherein the kit comprises:
[0704] Two syringes,
[0705] wherein the first syringe comprises the first container and the second container; and
[0706] wherein the second syringe comprises the third container and the fourth container;
[0707] wherein the first component and the second component are in powder form;
[0708] wherein the first syringe and the second syringe are configured to be fluidly connectable to each other so that the first container and the second container can be placed in fluid communication with the third container and the fourth container, respectively, to facilitate mixing of the first component with the solvent in the third container to form a solution of the first component in the first container, and to facilitate mixing of the second component with the solvent in the fourth container to form a solution of the second component in the second container,
[0709] The first syringe is further configured to mix the solution of the first component with the solution of the second component to form a hydrogel-forming composition for forming a hydrogel tissue sealant.
[0710] 178. The kit of any one of embodiments 173 to 177, wherein the first component further comprises an antioxidant.
[0711] 179. The kit of any one of embodiments 173 to 178, wherein the second component further comprises a surfactant and / or a cross-linking initiator.
[0712] 180. The kit of any one of embodiments 173 to 179, wherein the solution of the first component mixed with the solution of the second component provides the hydrogel-forming composition of any one of embodiments 1 to 16.
[0713] 181. The hydrogel-forming composition of any one of embodiments 155 to 170, or prepared using the kit of any one of embodiments 173 to 180, for use in a method of treatment by surgery.
[0714] 182. The hydrogel-forming composition for use according to embodiment 181, wherein the method of treatment by surgery comprises delivering the hydrogel-forming composition to a tissue site and forming a hydrogel tissue sealant at the tissue site.
[0715] 183. The hydrogel-forming composition for use according to embodiment 181 or 182, wherein the treatment by surgery is a lung biopsy procedure, and wherein the composition is used to prevent or reduce the risk of pneumothorax during or after the lung biopsy procedure.
[0716] 184. A hydrogel-forming composition for use according to any one of embodiments 181 to 183, wherein the composition is used to prevent or reduce the risk of pneumothorax during a lung biopsy procedure in a patient, wherein the hydrogel-forming composition is delivered to the pleural cavity of the patient to form a hydrogel tissue sealant through which a biopsy sample is obtained.
Claims
1. A hydrogel-forming composition for forming a hydrogel tissue sealant, comprising: The first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula: G-LM-PEG-LM-G; in: PEG is polyethylene glycol; Each LM is independently selected from the following bifunctional linking moieties: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 )b-C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula is -C(O)-(CH 2 )c-C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; the formula -C(O)-O-(CH 2 )d—O—C(O)— dicarbonate diradical, wherein d is an integer from 1 to 10; formula—N(H)—C(O)—(CH 2 )d—C(O)—containing amide diradical, wherein d is an integer from 1 to 10; 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diamino group of the formula —R—C(O)—, —R—C(O)—(CH 2 )c—C(O)—,—R—C(O)—O—(CH 2 )d—O—C(O)—,—R—N(H)—C(O)—(CH 2 )d—C(O)—or—R—(CH 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; and a second component comprising a protein capable of being cross-linked with the cross-linking agent; one or more solvents capable of dissolving the first component and the second component; and surfactants; When the first component, the second component and the surfactant are all dissolved in the one or more solvents, the cross-linking agent cross-links with the protein to form the hydrogel tissue sealant.
2. A hydrogel-forming composition for forming a hydrogel tissue sealant, comprising: A crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula: G-LM-PEG-LM-G; in: PEG is polyethylene glycol; Each LM is independently selected from the following bifunctional linking moieties: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 )b-C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula is -C(O)-(CH 2 )c-C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; the formula -C(O)-O-(CH 2 )d—O—C(O)— dicarbonate diradical, wherein d is an integer from 1 to 10; formula—N(H)—C(O)—(CH 2 )d—C(O)—containing amide diradical, wherein d is an integer from 1 to 10; 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diamino group of the formula —R—C(O)—, —R—C(O)—(CH 2 )c—C(O)—,—R—C(O)—O—(CH 2 )d—O—C(O)—,—R—N(H)—C(O)—(CH 2 )d—C(O)—or—R—(CH 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; a protein capable of being cross-linked with the cross-linking agent; one or more solvents capable of dissolving the first component and the second component; and surfactants; When the cross-linking agent, the protein and the surfactant are all dissolved in the one or more solvents, the cross-linking agent and the protein are cross-linked to form the hydrogel tissue sealant.
3. A hydrogel-forming composition for forming a hydrogel tissue sealant, comprising: The first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula: G-LM-PEG-LM-G; in: PEG is polyethylene glycol; Each LM is independently selected from the following bifunctional linking moieties: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 )b-C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula is -C(O)-(CH 2 )c-C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; the formula -C(O)-O-(CH 2 )d—O—C(O)— dicarbonate diradical, wherein d is an integer from 1 to 10; formula—N(H)—C(O)—(CH 2 )d—C(O)—containing amide diradical, wherein d is an integer from 1 to 10; 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diamino group of the formula —R—C(O)—, —R—C(O)—(CH 2 )c—C(O)—,—R—C(O)—O—(CH 2 )d—O—C(O)—,—R—N(H)—C(O)—(CH 2 )d—C(O)—or—R—(CH 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; and a second component comprising a protein capable of being cross-linked with the cross-linking agent; and a first solvent and a second solvent, wherein the first solvent is capable of dissolving the first component and the second solvent is capable of dissolving the second component; wherein when the second component is dissolved in the second solvent, the pH of the solution of the second component in the second solvent is greater than or equal to 10.2 and less than or equal to 10.6; and wherein when the first component is dissolved in the first solvent and combined with the solution of the second component in the second solvent, a cross-linked solution of the first component and the second component is formed.
4. A hydrogel-forming composition for forming a hydrogel tissue sealant, comprising: The first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula: G-LM-PEG-LM-G; in: PEG is polyethylene glycol; Each LM is independently selected from the following bifunctional linking moieties: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 )b-C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula is -C(O)-(CH 2 )c-C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; the formula -C(O)-O-(CH 2 )d—O—C(O)— dicarbonate diradical, wherein d is an integer from 1 to 10; formula—N(H)—C(O)—(CH 2 )d—C(O)—containing amide diradical, wherein d is an integer from 1 to 10; 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diamino group of the formula —R—C(O)—, —R—C(O)—(CH 2 )c—C(O)—,—R—C(O)—O—(CH 2 )d—O—C(O)—,—R—N(H)—C(O)—(CH 2 )d—C(O)—or—R—(CH 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; and a second component comprising a protein capable of being cross-linked with the cross-linking agent; and One or more solvents capable of dissolving the first component and the second component such that when the first component and the second component are individually mixed with the one or more solvents, at least the second component can have a dissolution time of less than or equal to 30 seconds at 25°C.
5. A method of forming a hydrogel tissue sealant, wherein include: A first component is dissolved in a first solvent, wherein the first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula: G-LM-PEG-LM-G; in: PEG is polyethylene glycol; Each LM is independently selected from the following bifunctional linking moieties: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 )b-C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula is -C(O)-(CH 2 )c-C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; the formula -C(O)-O-(CH 2 )d—O—C(O)— dicarbonate diradical, wherein d is an integer from 1 to 10; formula—N(H)—C(O)—(CH 2 )d—C(O)—containing amide diradical, wherein d is an integer from 1 to 10; 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diamino group of the formula —R—C(O)—, —R—C(O)—(CH 2 )c—C(O)—,—R—C(O)—O—(CH 2 )d—O—C(O)—,—R—N(H)—C(O)—(CH 2 )d—C(O)—or—R—(CH 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; dissolving a second component in a second solvent, wherein the second component comprises a protein capable of being cross-linked with the cross-linking agent, and The dissolved first component is combined with the dissolved second component to form a hydrogel-forming composition comprising the cross-linking agent, the protein, and a surfactant to induce cross-linking of the cross-linking agent with the protein to form the hydrogel tissue sealant.
6. A method of forming a hydrogel tissue sealant, wherein include: A first component is dissolved in a first solvent, wherein the first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula: G-LM-PEG-LM-G; in: PEG is polyethylene glycol; Each LM is independently selected from the following bifunctional linking moieties: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 )b-C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula is -C(O)-(CH 2 )c-C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; the formula -C(O)-O-(CH 2 )d—O—C(O)— dicarbonate diradical, wherein d is an integer from 1 to 10; formula—N(H)—C(O)—(CH 2 )d—C(O)—containing amide diradical, wherein d is an integer from 1 to 10; 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diamino group of the formula —R—C(O)—, —R—C(O)—(CH 2 )c—C(O)—,—R—C(O)—O—(CH 2 )d—O—C(O)—,—R—N(H)—C(O)—(CH 2 )d—C(O)—or—R—(CH 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; dissolving a second component in a second solvent, wherein the second component comprises a protein capable of being cross-linked with the cross-linking agent, and The dissolved first component is combined with the dissolved second component to form a hydrogel-forming composition comprising the cross-linking agent and the protein, thereby inducing cross-linking of the cross-linking agent with the protein to form the hydrogel tissue sealant such that the cross-linking is characterized by a gel time of less than or equal to 20 seconds.
7. A method of forming a hydrogel tissue sealant, wherein include: A first component is dissolved in a first solvent to form a solution of the first component, wherein the first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula: G-LM-PEG-LM-G; in: PEG is polyethylene glycol; Each LM is independently selected from the following bifunctional linking moieties: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 )b-C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula is -C(O)-(CH 2 )c-C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; the formula -C(O)-O-(CH 2 )d—O—C(O)— dicarbonate diradical, wherein d is an integer from 1 to 10; formula—N(H)—C(O)—(CH 2 )d—C(O)—containing amide diradical, wherein d is an integer from 1 to 10; 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diamino group of the formula —R—C(O)—, —R—C(O)—(CH 2 )c—C(O)—,—R—C(O)—O—(CH 2 )d—O—C(O)—,—R—N(H)—C(O)—(CH 2 )d—C(O)—or—R—(CH 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; dissolving a second component in a second solvent to form a solution of the second component, wherein the second component comprises a protein capable of being cross-linked with the cross-linking agent, and wherein the pH of the solution of the second component is greater than or equal to 10.2 and less than or equal to 10.6, and The solution of the first component is combined with the solution of the second component to form a hydrogel-forming composition comprising the cross-linking agent and the protein, thereby inducing cross-linking of the cross-linking agent with the protein to form the hydrogel tissue sealant.
8. A method of forming a hydrogel tissue sealant, wherein include: A first component is dissolved in a first solvent, wherein the first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula: G-LM-PEG-LM-G; in: PEG is polyethylene glycol; Each LM is independently selected from the following bifunctional linking moieties: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 )b-C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula is -C(O)-(CH 2 )c-C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; the formula -C(O)-O-(CH 2 )d—O—C(O)— dicarbonate diradical, wherein d is an integer from 1 to 10; formula—N(H)—C(O)—(CH 2 )d—C(O)—containing amide diradical, wherein d is an integer from 1 to 10; 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diamino group of the formula —R—C(O)—, —R—C(O)—(CH 2 )c—C(O)—,—R—C(O)—O—(CH 2 )d—O—C(O)—,—R—N(H)—C(O)—(CH 2 )d—C(O)—or—R—(CH 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; dissolving a second component in a second solvent, wherein the second component comprises a protein capable of being cross-linked with the cross-linking agent, wherein the dissolution time of the second component in the second solvent at 25° C. is less than or equal to 30 seconds; and The dissolved first component is combined with the dissolved second component to form a hydrogel-forming composition comprising the cross-linking agent and the protein, thereby initiating cross-linking of the cross-linking agent with the protein to form the hydrogel tissue sealant.
9. A method of forming a hydrogel tissue sealant, wherein include: A hydrogel-forming composition is formed, the hydrogel-forming composition comprising: A crosslinking agent which is a difunctional polyalkylene oxide based component of the formula: G-LM-PEG-LM-G; in: PEG is polyethylene glycol; Each LM is independently selected from the following bifunctional linking moieties: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 )b-C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula is -C(O)-(CH 2 )c-C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; the formula -C(O)-O-(CH 2 )d—O—C(O)— dicarbonate diradical, wherein d is an integer from 1 to 10; formula—N(H)—C(O)—(CH 2 )d—C(O)—containing amide diradical, wherein d is an integer from 1 to 10; 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diamino group of the formula —R—C(O)—, —R—C(O)—(CH 2 )c—C(O)—,—R—C(O)—O—(CH 2 )d—O—C(O)—,—R—N(H)—C(O)—(CH 2 )d—C(O)—or—R—(CH 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; a protein capable of being cross-linked with the cross-linking agent; and Surfactants; The hydrogel-forming composition, after being formed, causes the cross-linking agent to initiate cross-linking with the protein, thereby forming the hydrogel tissue sealant.
10. A method of sealing a tissue, wherein include: delivering a hydrogel-forming composition to a tissue site, wherein the hydrogel-forming composition comprises the reaction product of: The first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula: G-LM-PEG-LM-G; in: PEG is polyethylene glycol; Each LM is independently selected from the following bifunctional linking moieties: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 )b-C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula is -C(O)-(CH 2 )c-C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; the formula -C(O)-O-(CH 2 )d—O—C(O)— dicarbonate diradical, wherein d is an integer from 1 to 10; formula—N(H)—C(O)—(CH 2 )d—C(O)—containing amide diradical, wherein d is an integer from 1 to 10; 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diamino group of the formula —R—C(O)—, —R—C(O)—(CH 2 )c—C(O)—,—R—C(O)—O—(CH 2 )d—O—C(O)—,—R—N(H)—C(O)—(CH 2 )d—C(O)—or—R—(CH 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; and a second component comprising a protein capable of being cross-linked with the cross-linking agent; and The hydrogel-forming composition further comprises a surfactant.
11. A method of sealing a tissue, wherein include: delivering a hydrogel-forming composition to a tissue site, wherein the hydrogel-forming composition is the reaction product of: A solution of a first component comprising a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula: G-LM-PEG-LM-G; in: PEG is polyethylene glycol; Each LM is independently selected from the following bifunctional linking moieties: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 )b-C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula is -C(O)-(CH 2 )c-C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; the formula -C(O)-O-(CH 2 )d—O—C(O)— dicarbonate diradical, wherein d is an integer from 1 to 10; formula—N(H)—C(O)—(CH 2 )d—C(O)—containing amide diradical, wherein d is an integer from 1 to 10; 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diamino group of the formula —R—C(O)—, —R—C(O)—(CH 2 )c—C(O)—,—R—C(O)—O—(CH 2 )d—O—C(O)—,—R—N(H)—C(O)—(CH 2 )d—C(O)—or—R—(CH 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; and A solution of a second component, the second component comprising a protein capable of being cross-linked with the cross-linking agent, wherein the pH of the solution of the second component is greater than or equal to 10.2 and less than or equal to 10.
6.
12. A method of sealing a tissue, wherein include: A hydrogel-forming composition is delivered to a tissue site, wherein the hydrogel composition comprises the reaction product of: The first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula: G-LM-PEG-LM-G; in: PEG is polyethylene glycol; Each LM is independently selected from the following bifunctional linking moieties: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 )b-C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula is -C(O)-(CH 2 )c-C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; the formula -C(O)-O-(CH 2 )d—O—C(O)— dicarbonate diradical, wherein d is an integer from 1 to 10; formula—N(H)—C(O)—(CH 2 )d—C(O)—containing amide diradical, wherein d is an integer from 1 to 10; 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diamino group of the formula —R—C(O)—, —R—C(O)—(CH 2 )c—C(O)—,—R—C(O)—O—(CH 2 )d—O—C(O)—,—R—N(H)—C(O)—(CH 2 )d—C(O)—or—R—(CH 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; and a second component comprising a protein capable of being cross-linked with the cross-linking agent; and A hydrogel tissue sealant is formed at the tissue site via a cross-linking reaction characterized by a gel time of less than or equal to 20 seconds.
13. A kit for forming a hydrogel tissue sealant, comprising: A first component contained in a first container, wherein the first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula: G-LM-PEG-LM-G; in: PEG is polyethylene glycol; Each LM is independently selected from the following bifunctional linking moieties: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 )b-C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula is -C(O)-(CH 2 )c-C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; the formula -C(O)-O-(CH 2 )d—O—C(O)— dicarbonate diradical, wherein d is an integer from 1 to 10; formula—N(H)—C(O)—(CH 2 )d—C(O)—containing amide diradical, wherein d is an integer from 1 to 10; 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diamino group of the formula —R—C(O)—, —R—C(O)—(CH 2 )c—C(O)—,—R—C(O)—O—(CH 2 )d—O—C(O)—,—R—N(H)—C(O)—(CH 2 )d—C(O)—or—R—(CH 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; and A second component is contained in a second container, wherein the second component comprises a protein capable of being cross-linked with the cross-linking agent, and a surfactant.
14. A kit for forming a hydrogel tissue sealant, comprising: A first component in powder form contained in a first container, wherein the first component comprises a crosslinking agent, wherein the crosslinking agent is a difunctional polyalkylene oxide-based component of the formula: G-LM-PEG-LM-G; in: PEG is polyethylene glycol; Each LM is independently selected from the following bifunctional linking moieties: a carbonate digroup of formula -C(O)-; a digroup of formula -(CH 2 )b-C(O)- monoester diradical, wherein b is an integer from 1 to 10; the formula is -C(O)-(CH 2 )c-C(O)-, wherein c is an integer from 1 to 10 and wherein the aliphatic portion of the group may be saturated or unsaturated; the formula -C(O)-O-(CH 2 )d—O—C(O)— dicarbonate diradical, wherein d is an integer from 1 to 10; formula—N(H)—C(O)—(CH 2 )d—C(O)—containing amide diradical, wherein d is an integer from 1 to 10; 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10 and d is an integer from 1 to 10; and a diamino group of the formula —R—C(O)—, —R—C(O)—(CH 2 )c—C(O)—,—R—C(O)—O—(CH 2 )d—O—C(O)—,—R—N(H)—C(O)—(CH 2 )d—C(O)—or—R—(CH 2 )c—C(O)—N(H)—(CH 2 )d—, wherein c is an integer from 1 to 10, d is an integer from 1 to 10, and R is a polymer or copolymer having 1 to 10 monomeric lactide, glycolide, trimethylene carbonate, caprolactone or p-dioxanone fragments; and each G is a leaving group independently selected from the group consisting of N-oxysuccinimidyl, N-oxymaleimidyl, N-oxyphthalimidyl, nitrophenoxy, N-oxyimidazolyl, and trifluoroethanesulfonyl; a second component in powder form contained in a second container, wherein the second component comprises a protein capable of cross-linking with the cross-linking agent; a first aqueous hydrating solution contained in a third container, wherein the first aqueous hydrating solution is capable of dissolving the first component; as well as A second aqueous hydrating solution is contained within a fourth container, wherein the second aqueous hydrating solution is capable of dissolving the second component.
15. A kit for forming a hydrogel tissue sealant, comprising: one or more syringes collectively comprising at least three separate containers, wherein a first container comprises a first component in powder form, a second container comprises a second component in powder form, and at least a third container comprises one or more solvents, wherein the one or more syringes are configured such that the first container and the second container can be placed in fluid communication with the at least third container comprising the one or more solvents to facilitate mixing of the first component with the one or more solvents to form a solution of the first component and to facilitate mixing of the second component with the one or more solvents to form a solution of the second component, and wherein the one or more syringes are further configured to mix the solution of the first component with the solution of the second component to form a cross-linked solution of the first component and the second component that is capable of forming the hydrogel tissue sealant; The first component comprises an electrophilic biodegradable polymer, and the second component comprises a nucleophilic biodegradable polymer capable of cross-linking with the electrophilic biodegradable polymer.
